BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON: Form 990, tax year 2023

View the entire original 990 at ProPublica ↗

Organization: BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON (EIN 91-0653422)
Tax period: 2023-07-01 to 2024-06-30
Filed: 2025-05-07
IRS object ID: 202521279349302682
Schema version: 2023v6.0
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule I
Schedule J
Schedule K
Schedule O
Schedule R
Affiliated Group Schedule

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2025-05-07T13:06:07-05:00	ReturnTs
Tax Period End	2024-06-30	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	470617373	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	COMMONSPIRIT HEALTH	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	198 INVERNESS DRIVE WEST	AddressLine1Txt
City	ENGLEWOOD	CityNm
State Abbreviation	CO	StateAbbreviationCd
ZIP	80112	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2023-07-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	910653422	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	BENAROYA RESEARCH INSTITUTE AT VIRGINIA	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Business Name Control	BENA	BusinessNameControlTxt
Phone	2063426500	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	1201 NINTH AVENUE	AddressLine1Txt
City	SEATTLE	CityNm
State Abbreviation	WA	StateAbbreviationCd
ZIP	98101	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	MICHAEL LABOSIER	PersonNm
Person Title	TREASURER	PersonTitleTxt
Phone	2063426500	PhoneNum
Signature	2025-05-07	SignatureDt
Discuss With Paid Preparer	Yes (1)	DiscussWithPaidPreparerInd

Field	Value	IRS element (for citing)
IRS Responsible Prty Info Curr	Yes (1)	IRSResponsiblePrtyInfoCurrInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	HEATHER ADKINS	PreparerPersonNm
PTIN	P01725376	PTIN
Phone	3032989100	PhoneNum

Field	Value	IRS element (for citing)
Tax	2023	TaxYr
Build TS	2025-03-06 01:10:19Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Principal Officer	JANE BUCKNER MD	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	1201 NINTH AVENUE	AddressLine1Txt
City	SEATTLE	CityNm
State Abbreviation	WA	StateAbbreviationCd
ZIP	981012795	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$93,579,246	GrossReceiptsAmt
Group Return For Affiliates	0	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	HTTP://WWW.BENAROYARESEARCH.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1956	FormationYr
Legal Domicile State	WA	LegalDomicileStateCd
Activity Or Mission	TO ADVANCE THE SCIENCE THAT WILL PREDICT, PREVENT, REVERSE, AND CURE DISEASES OF THE IMMUNE SYSTEM.	ActivityOrMissionDesc
Voting Members Governing Body	12	VotingMembersGoverningBodyCnt
Voting Members Independent	12	VotingMembersIndependentCnt
Total Employee	320	TotalEmployeeCnt
Total Volunteers	0	TotalVolunteersCnt
Total Gross UBI	$0	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$75,771,314	PYContributionsGrantsAmt
CY Contributions Grants	$87,693,245	CYContributionsGrantsAmt
PY Program Service Revenue	$5,702,614	PYProgramServiceRevenueAmt
CY Program Service Revenue	$4,770,955	CYProgramServiceRevenueAmt
PY Investment Income	$282,812	PYInvestmentIncomeAmt
CY Investment Income	$407,521	CYInvestmentIncomeAmt
PY Other Revenue	$708,503	PYOtherRevenueAmt
CY Other Revenue	$707,525	CYOtherRevenueAmt
PY Total Revenue	$82,465,243	PYTotalRevenueAmt
CY Total Revenue	$93,579,246	CYTotalRevenueAmt
PY Grants And Similar Paid	$31,762,808	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$37,832,305	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$34,326,207	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$34,729,212	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$0	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$0	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$0	CYTotalFundraisingExpenseAmt
PY Other Expenses	$17,237,972	PYOtherExpensesAmt
CY Other Expenses	$14,954,605	CYOtherExpensesAmt
PY Total Expenses	$83,326,987	PYTotalExpensesAmt
CY Total Expenses	$87,516,122	CYTotalExpensesAmt
PY Revenues Less Expenses	-$861,744	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	$6,063,124	CYRevenuesLessExpensesAmt
Total Assets BOY	$94,354,363	TotalAssetsBOYAmt
Total Assets EOY	$96,038,082	TotalAssetsEOYAmt
Total Liabilities BOY	$42,735,678	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$40,329,397	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$51,618,685	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$55,708,685	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	TO ADVANCE THE SCIENCE THAT WILL PREDICT, PREVENT, REVERSE, AND CURE DISEASES OF THE IMMUNE SYSTEM SUCH AS AUTOIMMUNE DISEASE, ALLERGY, AND ASTHMA.	MissionDesc
Significant New Program Srvc	0	SignificantNewProgramSrvcInd
Significant Change	0	SignificantChangeInd
Expense	$53,492,397	ExpenseAmt
Grant	$36,122,063	GrantAmt
Revenue	$0	RevenueAmt
Desc	INTERVENTIONAL IMMUNOLOGY AND ADVANCEMENTS OF THE IMMUNE TOLERANCE NETWORK (ITN) ARE HIGHLIGHTED BELOW:FUNDING FOR THE IMMUNE TOLERANCE NETWORK (ITN) WAS INITIALLY AWARDED TO DR. JERRY NEPOM AT BRI IN 2014 BY THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) OF THE NATIONAL INSTITUTES OF HEALTH (NIH). IT WAS LATER RENEWED FOR A SECOND GRANT CYCLE IN 2021, PROVIDING APPROXIMATELY $27 MILLION ANNUALLY TO SUPPORT THE ITN. THIS RESEARCH CONSORTIUM, ESTABLISHED IN 1999, PRIMARILY FOCUSES ON DEVELOPING NEW TOLEROGENIC APPROACHES FOR TREATING AND PREVENTING DISEASES IN THREE CLINICAL AREAS: ASTHMA AND ALLERGIC DISEASES, AUTOIMMUNE DISEASES, AND IMMUNE-MEDIATED REJECTION OF TRANSPLANTED SOLID ORGANS, TISSUES, AND CELLS. BRI, AS THE PRIME RECIPIENT OF THIS GRANT, IS RESPONSIBLE FOR MANAGING THE OVERALL GRANT FROM NIAID, INCLUDING OVERSEEING ALL ASPECTS OF THE NETWORK'S INFRASTRUCTURE. AS OF 2022 FOLLOWING THE RETIREMENT OF DR. JERRY NEPOM, DR. JANE BUCKNER, PRESIDENT OF BRI, ASSUMED THE ROLE OF PRINCIPAL INVESTIGATOR OF THE ITN GRANT. DR. BUCKNER SERVES ON THE ITN STEERING COMMITTEE (NSC) AND THE ITN NETWORK EXECUTIVE COMMITTEE (NEC), AND PLAYED AN ACTIVE ROLE IN BOTH COMMITTEES AT OUR BIANNUAL IN-PERSON MEETINGS, PLAYING A CRITICAL ROLE IN TRACKING PROGRESS TOWARDS NETWORK GOALS AND DEVELOPING STRATEGIES TO MEET NETWORK OBJECTIVES.KEY OUTCOMES DURING THIS PERIOD INCLUDE:THE ITN CROSS-NETWORK INTEGRATION: SINCE 2014, THE ITN HAS EXCELLED WITH A STRONG FOCUS ON METICULOUS PLANNING AND COLLABORATION ACROSS THE ITN'S MAJOR CENTERS, LOCATED IN SEATTLE (BRI), SAN FRANCISCO (UNIVERSITY OF CALIFORNIA SAN FRANCISCO), DURHAM, NC (DUKE), BOSTON (BRIGHAM WOMEN'S HOSPITAL), ATLANTA (EMORY), AND ANN ARBOR (U OF MICHIGAN). THAT SUCCESSFUL COLLABORATION CONTINUED WITH THE FOLLOWING KEY OUTCOMES DURING THIS PERIOD:1. EFFECTIVE COLLABORATION WAS PARTICULARLY EVIDENT THIS PAST YEAR WITH THE PUBLICATION OF THE PRIMARY MANUSCRIPT FROM THE LEAP TRIO STUDY, THE SECOND FOLLOW-UP TO THE ITN'S GROUNDBREAKING LEAP STUDY, WHICH DEMONSTRATED THAT EARLY INTRODUCTION OF PEANUTS EFFECTIVELY HELPS PREVENT THE DEVELOPMENT OF PEANUT ALLERGY. THE FIRST FOLLOW-UP STUDY, LEAP-ON (2016), SHOWED THAT THIS PROTECTION PERSISTED EVEN AFTER A YEAR OF PEANUT AVOIDANCE (BETWEEN AGES 5 AND 6). NOW, DATA FROM THE LEAP TRIO STUDY, WHICH EXAMINED THE DURABILITY OF PEANUT TOLERANCE AT 144 MONTHS (AGE 12) AFTER YEARS OF AD LIBITUM PEANUT CONSUMPTION, DEMONSTRATE THAT TOLERANCE TO PEANUTS LASTS INTO ADOLESCENCE, IRRESPECTIVE OF SUBSEQUENT PEANUT CONSUMPTION. THESE FINDINGS HIGHLIGHT THAT LONG-TERM PREVENTION AND TOLERANCE IN FOOD ALLERGY CAN BE ACHIEVED.2. IN LINE WITH THE NIH DATA SHARING POLICY, THE ITN COORDINATING CENTER REVIEWED AND APPROVED 14 SAMPLE AND DATA SHARING REQUESTS THROUGH ITN TRIALSHARE, THE ITN'S DATA-SHARING PORTAL.3. OPERATIONS AND CLINICAL TRIAL SUPPORT: THE ITN COORDINATING CENTER AT BRI ISSUED OVER 275 SUBAWARDS DURING THIS REPORTING PERIOD TO SUPPORT 23 ACTIVE ITN CLINICAL TRIALS AND NUMEROUS SUPPORTING ITN MECHANISTIC TRIALS. DURING THIS REPORTING PERIOD, THE COORDINATING CENTER ALSO COMPLETED THE CONTRACTING COMPONENT FOR ONE OF THE TWO NIAID-SPONSORED COVID-19 CLINICAL TRIALS THEY HAD SUPPORTED AND FUNDED THROUGH ADMINISTRATIVE SUPPLEMENTS, WITH THE FINAL STUDY SET TO CONCLUDE IN Q3 2025.4. SUPPLEMENTAL FUNDING / PARTNERSHIPS: THE ITN COORDINATING CENTER CONTINUED TO FOCUS ON IDENTIFYING ADDITIONAL OPPORTUNITIES FOR SUPPLEMENTAL FUNDING AND FUNDING PARTNERSHIPS.A) SUPPLEMENTAL FUNDING: THE ITN COORDINATING CENTER AT BRI SUCCESSFULLY SUBMITTED ONE SUPPLEMENTAL FUNDING REQUEST IN 2023, WHICH WILL PROVIDE AN ADDITIONAL $1 MILLION PER YEAR THROUGH 2027. B) PARTNERSHIPS: THE ITN SUCCESSFULLY FULFILLED ITS PARTNERSHIP WITH A PHARMACEUTICAL COMPANY FOR PARTIAL FUNDING FOR AN ITN STUDY THAT ENDED IN LATE 2023. C) PARTNERSHIPS: SUCCESSFULLY NEGOTIATED COMMITMENTS FOR PARTIAL FINANCIAL SUPPORT FOR THREE ITN TRIALS TOTALING $7.3 MILLION. THOSE FUNDING AGREEMENTS WILL BE FINALIZED IN EARLY 2025. 5. PUBLICATION ACTIVITY: IN TOTAL, 35 ITN PUBLICATIONS WERE PUBLISHED DURING THIS REPORTING PERIOD IN PRESTIGIOUS RESEARCH JOURNALS AND PRESENTED AT DOMESTIC AND INTERNATIONAL RESEARCH CONFERENCES. THESE PUBLICATIONS REPRESENTED ITN RESEARCH IN ALL THERAPEUTIC FOCUS AREAS: AUTOIMMUNITY, TRANSPLANTATION, AND ALLERGY.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$12,744,134	ExpenseAmt
Grant	$934,337	GrantAmt
Revenue	$0	RevenueAmt
Desc	SCREENING FOR AUTOIMMUNE DISEASESIN 2024, BRI LAUNCHED ONE OF THE FIRST-EVER SCREENING INITIATIVES FOR AUTOIMMUNE DISEASES IN PRIMARY CARE. WHILE SCREENING IS COMMONPLACE FOR CANCER AND HEART DISEASE, SCREENING FOR AUTOIMMUNE DISEASES HAS NOT BEEN WIDELY AVAILABLE. A TEAM FROM BRI'S CENTER FOR INTERVENTIONAL IMMUNOLOGY LED BY CATE SPEAKE, PHD, AND SANDRA LORD, MD, LAUNCHED A STUDY TO IMPLEMENT SCREENING FOR TYPE 1 DIABETES, RHEUMATOID ARTHRITIS AND CELIAC DISEASE IN PRIMARY CARE. THE RESEARCH TEAM HAS NOW LAUNCHED SCREENING EFFORTS IN TWO VIRGINIA MASON FRANCISCAN HEALTH PRIMARY CARE CLINICS, EXAMINING HOW TO MAKE TESTING AS EASY AND EFFICIENT AS POSSIBLE FOR PATIENTS AND PROVIDERS. ONCE THIS STUDY IS COMPLETE, RESEARCHERS HOPE TO IMPLEMENT THIS SCREENING ACROSS VIRGINIA MASON FRANCISCAN HEALTH AND ULTIMATELY MAKE IT A STANDARD PART OF PRIMARY CARE. THIS COULD HELP VAST NUMBERS OF PEOPLE ACROSS THE COUNTRY UNDERSTAND THEIR RISK, START TREATMENT EARLY AND AVOID SEVERE COMPLICATIONS LIKE DIABETIC KETOACIDOSIS IN T1D.THIS STUDY IS FUNDED BY A GENEROUS DONATION FROM THE JOLENE MCCAW FAMILY FOUNDATION. NEW FRONTIERS IN TISSUE-SPECIFIC IMMUNOLOGYTRADITIONALLY, SCIENTISTS HAVE STUDIED IMMUNE SYSTEM DISEASES BY LOOKING AT BLOOD SAMPLES. BUT THEY'VE ALSO KNOWN THAT STUDYING THE ACTUAL TISSUE THAT THOSE DISEASES AFFECT THE JOINTS IN RHEUMATOID ARTHRITIS (RA) OR THE SKIN IN SCLERODERMA COULD PROVIDE EVEN MORE INFORMATION. THE PROBLEM IS, TISSUE IS HARD TO COME BY. IT'S MORE FEASIBLE TO COLLECT AND STUDY BLOOD SAMPLES THAN IT IS TO DO THE SAME WITH TISSUE FROM JOINTS OR THE SKIN. THAT'S WHY TISSUE-SPECIFIC IMMUNOLOGY HAS BECOME A CORE FOCUS FOR BRI, EXPLORING NEW WAYS TO STUDY TISSUES IN THE DISEASES WHERE THEY HAPPEN. THANKS TO OUR PARTNERSHIP WITH VIRGINIA MASON FRANCISCAN HEALTH, BRI'S EDDIE JAMES, PHD, IS STUDYING RHEUMATOID ARTHRITIS (RA) IN TISSUE SAMPLES FROM PEOPLE WHO HAVE HAD JOINT REPLACEMENTS. INSTEAD OF DISCARDING THE JOINT TISSUE REMOVED DURING SURGERY, SOME PATIENTS OPT TO DONATE THAT TISSUE TO RESEARCH. DR. JAMES AND HIS TEAM CAN THEN STUDY THAT TISSUE TO BETTER UNDERSTAND EXACTLY WHY IMMUNE SYSTEM CELLS ARE ATTACKING THE JOINTS IN RA AND HOW WE CAN STOP THAT ATTACK TO TREAT OR PREVENT RA. BRI'S PETER MORAWSKI, PHD, AND HIS TEAM STUDY AUTOIMMUNE DISEASES THAT AFFECT THE SKIN INCLUDING PSORIASIS AND SCLERODERMA. THEY STUDY SKIN TISSUE IN THREE DIFFERENT FORMS: 3D ENGINEERED MODELS, DONATED TISSUE SAMPLES FROM PEOPLE WHO HAVE HAD TUMMY TUCKS, AND DONATED PUNCH BIOPSIES (TISSUE SAMPLES ABOUT THE SIZE OF A PENCIL ERASER) FROM PEOPLE WITH AND WITHOUT SCLERODERMA. A GROUNDBREAKING TOOL CALLED SPATIAL TRANSCRIPTOMICS IS HELPING THE TEAM BETTER UNDERSTAND HOW SCLERODERMA STARTS AND PROGRESSES. THIS TECHNOLOGY LETS THE RESEARCHERS LOOK DEEP INTO THE TISSUE AND SEE THE EXACT LOCATIONS OF INDIVIDUAL CELLS, HOW THEY INTERACT, AND EVEN THEIR INDIVIDUAL GENE EXPRESSION. THEY'LL USE THIS TOOL TO STUDY ONE AREA OF SKIN THAT SHOWS SYMPTOMS (SKIN THAT'S THICK, WAXY AND SOMETIMES A DIFFERENT COLOR THAN UNAFFECTED SKIN) AND ANOTHER AREA NOT SHOWING SIGNS OF DISEASE IN THE SAME PERSON. THEN THEY'LL DIRECTLY COMPARE THEM SIDE-BY-SIDE. THIS WILL HELP THE RESEARCH TEAM BETTER UNDERSTAND HOW THE DISEASE STARTS AND PROGRESSES AND MOVE CLOSER TO BETTER TREATMENTS AND PREVENTION. BRI'S JAMES LORD, MD, PHD, IS A PHYSICIAN-RESEARCHER FOCUSED ON INFLAMMATORY BOWEL DISEASES (IBD). ONE OF THE BIGGEST CHALLENGES OF TREATING IBD IS THAT THERE ARE MANY DIFFERENT TREATMENTS AND NO WAY TO KNOW WHICH ONE WILL WORK BEST FOR WHICH PERSON. HIS TEAM IS WORKING TO CHANGE THAT BY STUDYING SMALL BIOPSY SAMPLES FROM COLONOSCOPIES FROM PEOPLE TAKING A MEDICINE CALLED VENDOLIZUMAB FOR IBD. THOSE SAMPLES WILL HELP HIS TEAM BETTER UNDERSTAND EXACTLY WHICH CELLS THE TREATMENT AFFECTS AND WHY IT WORKS FOR SOME PEOPLE BUT NOT OTHERS.	Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

Field	Value	IRS element (for citing)
Expense	$7,001,171	ExpenseAmt
Grant	$775,905	GrantAmt
Revenue	$0	RevenueAmt
Desc	STUDYING DOWN SYNDROME AND TYPE 1 DIABETES (T1D) TO UNDERSTAND HOW AUTOIMMUNE DISEASES STARTIN OCTOBER 2023, BRI RECEIVED THE IMMUNE DRIVERS OF AUTOIMMUNE DISEASE (IDAD) GRANT. THIS STUDY IS EXAMINING PEOPLE AT HIGHER RISK FOR DEVELOPING AUTOIMMUNE DISEASES THOSE WITH DOWN SYNDROME (DS) AND THOSE WITH AUTOANTIBODIES FOR TYPE 1 DIABETES (T1D) TO BETTER UNDERSTAND HOW AND WHY AUTOIMMUNE DISEASES DEVELOP. THIS WORK BUILDS ON PREVIOUS FINDINGS FROM BERNARD KHOR, MD, PHD, WHICH FOUND THAT INDIVIDUALS WITH DS EXPERIENCE PREMATURE IMMUNE AGING AND ARE SIGNIFICANTLY MORE LIKELY TO DEVELOP CONDITIONS LIKE AUTOIMMUNITY AND INFECTIONS. THE IDAD GRANT WILL SUPPORT A MULTIDISCIPLINARY EFFORT LED BY BRI SCIENTISTS TO IDENTIFY THE GENETIC, MOLECULAR, AND ENVIRONMENTAL FACTORS THAT DRIVE AUTOIMMUNE DISEASE PROGRESSION. RESEARCHERS WILL COMPARE IMMUNE PROFILES OF INDIVIDUALS WITH DS WITH THOSE AT RISK FOR T1D TO UNCOVER COMMON MECHANISMS OF IMMUNE DYSFUNCTION. THE STUDY WILL DRAW FROM BRI'S EXTENSIVE BIOREPOSITORIES, PROVIDING A VALUABLE RESOURCE FOR ADVANCING KNOWLEDGE IN THIS FIELD. THIS RESEARCH HAS THE POTENTIAL TO INFORM NEW TREATMENTS AND PREVENTION FOR AUTOIMMUNE DISEASES IN PEOPLE WITH AND WITHOUT DS.	Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp

Field	Value	IRS element (for citing)
Expense	$409,078	ExpenseAmt
Grant	$0	GrantAmt
Revenue	$4,770,955	RevenueAmt
Desc	UNDERSTANDING HOW LUPUS STARTS AND PROGRESSESSCIENTISTS HAVE LONG KNOWN THAT AN ANTIBODY CALLED IGG PLAYS A BIG ROLE IN LUPUS. BUT BRI'S HAYLEY WATERMAN, PHD, WANTED TO KNOW - DO OTHER ANTIBODIES PLAY A ROLE IN LUPUS TOO? SHE LAUNCHED A STUDY EXAMINING WHETHER AN ANTIBODY CALLED IGA MAY ALSO PLAY A ROLE. SHE FOUND THAT IGA PLAYED A SMALL ROLE IN LUPUS. BUT WHEN SHE TESTED IGA AND IGG TOGETHER, SHE FOUND A MUCH BIGGER IMMUNE SYSTEM RESPONSE THAN EITHER ANTIBODY ACTING ALONE. DR. WATERMAN'S FINDINGS COULD LEAD TO BREAKTHROUGHS IN BOTH DIAGNOSING AND TREATING LUPUS. LUPUS IS OFTEN DIFFICULT TO DIAGNOSE BECAUSE IT HAS A WIDE RANGE OF SYMPTOMS THAT OFTEN COME AND GO. AND CURRENTLY AVAILABLE TREATMENTS DON'T WORK EQUALLY WELL FOR EVERYONE. SO RESEARCH INTO SIGNS OF IGA AND IGG WORKING TOGETHER - AND FINDING WAYS TO DISRUPT THAT - HOLDS TREMENDOUS PROMISE FOR ADVANCING CARE FOR THIS DEBILITATING DISEASE.AFTER THIS INITIAL FINDING, DR. WATERMAN AND HER MENTOR, JESSICA HAMERMAN, PHD, RECEIVED SIGNIFICANT NIH FUNDING TO FURTHER EXPLORE THESE FINDINGS. THEY PLAN TO STUDY EXACTLY HOW IGA AND IGG WORK TOGETHER TO CAUSE THIS SIGNIFICANT IMMUNE SYSTEM RESPONSE IN LUPUS. THEY'RE ALSO INTERESTED IN STUDYING WHETHER THE PRESENCE OF IGA MIGHT EXPLAIN WHY LUPUS CAN HAVE SUCH A WIDE ARRAY OF SYMPTOMS. LUPUS CAN CAUSE EVERYTHING FROM A SKIN RASH TO ARTHRITIS TO KIDNEY AND LUNG PROBLEMS, BUT SCIENTISTS DON'T FULLY UNDERSTAND WHY IT AFFECTS PEOPLE IN DIFFERENT WAYS. THE RESEARCH TEAM WANTS TO FIND OUT IF IGA IS ASSOCIATED WITH CERTAIN SYMPTOMS OR MORE SEVERE DISEASE.CLINICAL RESEARCH PROGRAM BRI OVERSEES THE CLINICAL RESEARCH PROGRAM AT VIRGINIA MASON MEDICAL CENTER, UNIQUELY COMBINING THE EXPERTISE OF A WORLD-RENOWNED MEDICAL RESEARCH INSTITUTE WITH THE CARE OF A HEALTHCARE QUALITY LEADER. THE CLINICAL RESEARCH PROGRAM SUPPORTS VIRGINIA MASON CLINICAL INVESTIGATORS IN STUDIES ACROSS A WIDE VARIETY OF AUTOIMMUNE AND IMMUNE-MEDIATED DISEASES AND CONDITIONS, AS WELL AS A BROAD RANGE OF OTHER DISEASES SUCH AS CANCER AND CARDIAC DISEASE. THE CLINICAL RESEARCH PROGRAM STAFF ANNUALLY ENROLLS APPROXIMATELY 2,264 STUDY PARTICIPANTS INTO VIRGINIA MASON TRIALS.INNOVATION FUND AWARDESTABLISHED IN 2023, THE INNOVATION FUND AWARD IS GIVEN TWICE A YEAR TO INTERNAL RECIPIENTS AT BRI. THE OBJECTIVE IS TO FACILITATE DEVELOPMENT AND IMPLEMENTATION OF NEW TECHNOLOGIES THAT WILL ADVANCE WORK ACROSS OUR INSTITUTION, THROUGH THE FUNDING OF COLLABORATIVE PROJECTS. EACH AWARD IS FUNDED BY PHILANTHROPY. BRI'S REGULAR TRACK AND RESEARCH TRACK FACULTY ARE AWARD ELIGIBLE. PROJECTS ARE REQUIRED TO INCLUDE TWO OR MORE BRI FACULTY AND ADDRESS INNOVATIONS USEFUL TO MULTIPLE RESEARCH GROUPS WITHIN THE INSTITUTE. FURTHER, IT IS REQUIRED THAT THE PROTOCOLS AND RESULTS GENERATED IN THE PROJECT WILL BE MADE AVAILABLE TO ALL BRI INVESTIGATORS. AT THE END OF 2023, EDDIE JAMES, PHD, AND CAROLINE STEFANI, PHD, EARNED AN INNOVATION FUND GRANT TO COMBINE TWO GROUNDBREAKING TECHNOLOGIES: LAB-GROWN HUMAN BETA CELLS AND A STATE-OF-THE-ART MICROSCOPE. BETA CELLS ARE PANCREAS CELLS THAT THE IMMUNE SYSTEM ATTACKS IN T1D. PREVIOUSLY, THE ONLY WAY TO STUDY THESE CELLS WAS IF SOMEONE DIED AND DONATED THEIR BODY TO SCIENCE. IN 2023, BRI'S AISHA CALLEBAUT, PHD, TRAVELED TO BELGIUM TO LEARN A NEW WAY TO ACCESS THESE CELLS: GROWING THEM FROM HUMAN BETA CELLS. THE INNOVATION FUND GRANT SUPPORTED THE IMPLEMENTATION OF TOOLS AND TECHNOLOGY NEEDED TO GROW THESE CELLS AT BRI. NOW, DRS. JAMES AND STEFANI ARE EXAMINING THESE LAB-GROWN CELLS TO BETTER UNDERSTAND WHY IMMUNE SYSTEM CELLS ATTACK BETA CELLS IN T1D AND HOW THEY MIGHT MAKE BETA CELLS MORE RESILIENT TO THAT ATTACK. THIS TECHNIQUE AND INFRASTRUCTURE CAN ALSO BE USED TO ENGINEER OTHER TYPES OF IMMUNE CELLS - FROM NEURONS, TO SKIN CELLS TO GUT CELLS - OPENING THE DOOR TO ANSWER NEW AND IMPORTANT QUESTIONS ABOUT A WIDE VARIETY OF DISEASES. IN 2024, BRI PRESIDENT JANE BUCKNER, MD, AND OLIVER HARRISON, DPHIL, EARNED AN INNOVATION FUND GRANT TO IMPLEMENT NEW METHODS OF GENOME ENGINEERING IN HUMAN T CELLS AND MICE, USING CRISPR/CAS9 AND ADENO-ASSOCIATED VIRUS TECHNOLOGY. THIS COLLABORATION BETWEEN THE HARRISON AND BUCKNER LABS AIMS TO CREATE ADVANCED MODELS FOR STUDYING AUTOIMMUNE DISEASE.DR. BUCKNER'S TEAM WILL ENGINEER HUMAN T CELLS BY REINTRODUCING T CELL RECEPTOR SEQUENCES, ALLOWING RESEARCHERS TO STUDY AUTOREACTIVE T CELLS. MEANWHILE, DR. HARRISON'S GROUP WILL DEVELOP NEW TRANSGENIC MOUSE MODELS, INCLUDING MICE WITH B CELL RECEPTORS THAT RECOGNIZE BACTERIAL ANTIGENS. THESE INNOVATIVE APPROACHES WILL ENHANCE BRI'S ABILITY TO STUDY IMMUNE RESPONSE, IMPROVE DISEASE MODELS, AND BETTER UNDERSTAND THE ROLE OF B AND T CELLS IN AUTOIMMUNITY.	Desc

Field	Value	IRS element (for citing)
Total Other Prog Srvc Expense	$409,078	TotalOtherProgSrvcExpenseAmt
Total Other Prog Srvc Grant	$0	TotalOtherProgSrvcGrantAmt
Total Other Prog Srvc Revenue	$4,770,955	TotalOtherProgSrvcRevenueAmt
Total Program Service Expenses	$73,646,780	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (1)	DescribedInSection501c3Ind
Schedule B Required	Yes (1)	ScheduleBRequiredInd
Political Campaign Acty	0	PoliticalCampaignActyInd
Lobbying Activities	Yes (1)	LobbyingActivitiesInd
Subject To Proxy Tax	0	SubjectToProxyTaxInd
Donor Advised Fund	0	DonorAdvisedFundInd
Conservation Easements	0	ConservationEasementsInd
Collections Of Art	0	CollectionsOfArtInd
Credit Counseling	0	CreditCounselingInd
Donor Rstr Or Quasi Endowments	0	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (1)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	Yes (1)	ReportInvestmentsOtherSecInd
Report Program Related Invst	0	ReportProgramRelatedInvstInd
Report Other Assets	0	ReportOtherAssetsInd
Report Other Liabilities	Yes (1)	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (1)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	0	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	Yes (1)	ConsolidatedAuditFinclStmtInd
School Operating	0	SchoolOperatingInd
Foreign Office	0	ForeignOfficeInd
Foreign Activities	Yes (1)	ForeignActivitiesInd
More Than5000 K To Org	Yes (1)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	0	MoreThan5000KToIndividualsInd
Professional Fundraising	0	ProfessionalFundraisingInd
Fundraising Activities	0	FundraisingActivitiesInd
Gaming Activities	0	GamingActivitiesInd
Operate Hospital	0	OperateHospitalInd
Grants To Organizations	Yes (1)	GrantsToOrganizationsInd
Grants To Individuals	0	GrantsToIndividualsInd
Schedule J Required	Yes (1)	ScheduleJRequiredInd
Tax Exempt Bonds	Yes (1)	TaxExemptBondsInd
Invest Tax Exempt Bonds	0	InvestTaxExemptBondsInd
Escrow Account	0	EscrowAccountInd
On Behalf Of Issuer	Yes (1)	OnBehalfOfIssuerInd
Engaged In Excess Benefit Trans	0	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	0	PYExcessBenefitTransInd
Loan Outstanding	0	LoanOutstandingInd
Grant To Related Person	0	GrantToRelatedPersonInd
Business Rln With Org Mem	0	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	0	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	0	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	0	DeductibleNonCashContriInd
Deductible Art Contribution	0	DeductibleArtContributionInd
Terminate Operations	0	TerminateOperationsInd
Partial Liquidation	0	PartialLiquidationInd
Disregarded Entity	0	DisregardedEntityInd
Related Entity	Yes (1)	RelatedEntityInd
Related Organization Ctrl Ent	0	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	0	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	0	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (1)	ScheduleORequiredInd
IRP Document	65	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (1)	BackupWthldComplianceInd
Employee	320	EmployeeCnt
Employment Tax Returns Filed	Yes (1)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	0	UnrelatedBusIncmOverLimitInd
Foreign Financial Account	0	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	0	ProhibitedTaxShelterTransInd
Taxable Party Notification	0	TaxablePartyNotificationInd
Nondeductible Contributions	0	NondeductibleContributionsInd
Quid Pro Quo Contributions	0	QuidProQuoContributionsInd
Form8282 Property Disposed Of	0	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	0	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	0	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	0	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	0	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	0	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	12	GoverningBodyVotingMembersCnt
Independent Voting Member	12	IndependentVotingMemberCnt
Family Or Business Rln	0	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	0	DelegationOfMgmtDutiesInd
Change To Org Documents	0	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	0	MaterialDiversionOrMisuseInd
Members Or Stockholders	Yes (1)	MembersOrStockholdersInd
Election Of Board Members	Yes (1)	ElectionOfBoardMembersInd
Decisions Subject To Approva	Yes (1)	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (1)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (1)	MinutesOfCommitteesInd
Officer Mailing Address	0	OfficerMailingAddressInd
Local Chapters	0	LocalChaptersInd
Form990 Provided To Gvrn Body	0	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (1)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (1)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (1)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (1)	WhistleblowerPolicyInd
Document Retention Policy	Yes (1)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (1)	CompensationProcessCEOInd
Compensation Process Other	Yes (1)	CompensationProcessOtherInd
Investment In Joint Venture	0	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	WA	StatesWhereCopyOfReturnIsFldCd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	HELEN CLAGETT	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Phone	2063426503	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	1201 NINTH AVENUE	AddressLine1Txt
City	SEATTLE	CityNm
State Abbreviation	WA	StateAbbreviationCd
ZIP	98101	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (25 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Highest Compensated EmployeeHighestCompensatedEmployeeInd	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd
KETUL PATEL
CHIEF EXECUTIVE OFFICER VMFH	10.00	2.00	Yes (X)	$2,613,387	$0	$32,903
JANE BUCKNER MD
PRESIDENT	40.00	0.00	Yes (X)	$501,678	$0	$32,412
MARGARET MCCORMICK PHD
EXECUTIVE DIRECTOR & COO	40.00	0.00	Yes (X)	$303,699	$0	$35,478
WILLIAM KWOK PHD
RESEARCH MEMBER	40.00	0.00		$286,471	$0	$33,612	Yes (X)
DANIEL CAMPBELL PHD
DIRECTOR, CENTER FOR FUNDAMENTAL IMMUNOLOGY	40.00	0.00		$230,355	$0	$20,619	Yes (X)
JESSICA HAMERMAN PHD
DIRECTOR, ACADEMIC AFFAIRS	40.00	0.00		$229,026	$0	$18,505	Yes (X)
CARMEN MIKACENIC MD
ASSOCIATE RESEARCH MEMBER	40.00	0.00		$224,166	$0	$29,448	Yes (X)
PETER LINSLEY PHD
MEMBER, PRINCIPAL INVESTIGATOR	40.00	0.00		$220,411	$0	$33,924	Yes (X)
MICHAEL LABOSIER
CFO	40.00	0.00	Yes (X)	$186,969	$0	$27,689
CHUCK ARNOLD
DIRECTOR	2.00	2.00		$0	$0	$0		Yes (X)
BOB CARLILE
DIRECTOR	2.00	2.00		$0	$0	$0		Yes (X)
MIRIAM CHAMBLISS
CORPORATE SECRETARY / VP DIV GENERAL COUNSEL	2.00	2.00	Yes (X)	$0	$0	$0
ULI CHI PHD
DIRECTOR/CHAIR	2.00	2.00	Yes (X)	$0	$0	$0		Yes (X)
SISTER JUDE CONNELLY OSF
DIRECTOR (PARTIAL YEAR)	2.00	2.00		$0	$0	$0		Yes (X)
CAROLYN CORVI
DIRECTOR	2.00	2.00		$0	$0	$0		Yes (X)
SISTER RUTH GOODWIN OSF
DIRECTOR	2.00	2.00		$0	$0	$0		Yes (X)
TOD HAMACHEK
DIRECTOR	2.00	2.00		$0	$0	$0		Yes (X)
DENNIS HUNTHAUSEN
DIRECTOR	2.00	2.00		$0	$0	$0		Yes (X)
KAREN LEE
DIRECTOR	2.00	2.00		$0	$0	$0		Yes (X)
ROBERT LEMON
DIRECTOR/VICE CHAIR	2.00	2.00	Yes (X)	$0	$0	$0		Yes (X)
GREGG MEYER MD MSC
DIRECTOR	2.00	2.00		$0	$0	$0		Yes (X)
DAVID NOSACKA
TREASURER / SVP & CFO VMFH	0.00	2.00	Yes (X)	$0	$0	$0
JOHN OPPENHEIMER
DIRECTOR	2.00	2.00		$0	$0	$0		Yes (X)
MARVIN O'QUINN
DIRECTOR (PARTIAL YEAR)	2.00	2.00		$0	$0	$0		Yes (X)
DIANN PULS
DIRECTOR	2.00	2.00		$0	$0	$0		Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$4,796,162	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$264,590	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	91	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	0	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (1)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	Yes (1)	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (3 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
INFINITY BIOLOGIX LLC
PO BOX 23532	NEW YORK	NY	100873532	LABORATORY SERVICES	$351,620
NORTH FORK HOLDINGS LLC
1933 N MEACHAM RD STE 220	SCHAUMBURG	IL	60173	SOFTWARE CONSULTING	$160,957
FINLEY & COOK CPA
1421 E 45TH ST PO DRAWER 1447	SHAWNEE	OK	74802	SOFTWARE CONSULTING	$142,417

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	3	CntrctRcvdGreaterThan100KCnt
Government Grants	$64,307,227	GovernmentGrantsAmt
All Other Contributions	$23,386,018	AllOtherContributionsAmt
Total Contributions	$87,693,245	TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp (2 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt	Unrelated Business RevenueUnrelatedBusinessRevenueAmt	ExclusionExclusionAmt
COMMERCIAL STUDIES	621500	$4,450,908	$4,450,908	$0	$0
EXTERNAL CORE INCOME	621500	$320,047	$320,047	$0	$0

Field	Value	IRS element (for citing)
Total Program Service Revenue	$4,770,955	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$407,521	TotalRevenueColumnAmt
Exclusion	$407,521	ExclusionAmt

Gross Rents GrossRentsGrp

Field	Value	IRS element (for citing)
Real	$707,525	RealAmt

Less Rental Expenses LessRentalExpensesGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt

Rental Income Or Loss RentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Real	$707,525	RealAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$707,525	TotalRevenueColumnAmt
Exclusion	$707,525	ExclusionAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$93,579,246	TotalRevenueColumnAmt
Related Or Exempt Func Income	$4,770,955	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$1,115,046	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$35,991,061	TotalAmt
Program Services	$35,991,061	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$1,841,244	TotalAmt
Program Services	$1,841,244	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$890,702	TotalAmt
Program Services	$541,345	ProgramServicesAmt
Management And General	$349,357	ManagementAndGeneralAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$26,358,556	TotalAmt
Program Services	$18,309,091	ProgramServicesAmt
Management And General	$8,049,465	ManagementAndGeneralAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$2,384,735	TotalAmt
Program Services	$1,632,470	ProgramServicesAmt
Management And General	$752,265	ManagementAndGeneralAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$3,057,160	TotalAmt
Program Services	$2,092,778	ProgramServicesAmt
Management And General	$964,382	ManagementAndGeneralAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$2,038,059	TotalAmt
Program Services	$1,395,152	ProgramServicesAmt
Management And General	$642,907	ManagementAndGeneralAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$25,958	TotalAmt
Management And General	$25,958	ManagementAndGeneralAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$2,118,084	TotalAmt
Program Services	$1,590,061	ProgramServicesAmt
Management And General	$528,023	ManagementAndGeneralAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$90,948	TotalAmt
Program Services	$26,067	ProgramServicesAmt
Management And General	$64,881	ManagementAndGeneralAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$2,013,182	TotalAmt
Program Services	$793,016	ProgramServicesAmt
Management And General	$1,220,166	ManagementAndGeneralAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$3,442,015	TotalAmt
Program Services	$3,006,423	ProgramServicesAmt
Management And General	$435,592	ManagementAndGeneralAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$202,649	TotalAmt
Program Services	$157,940	ProgramServicesAmt
Management And General	$44,709	ManagementAndGeneralAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$46,713	TotalAmt
Program Services	$41,750	ProgramServicesAmt
Management And General	$4,963	ManagementAndGeneralAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$889,305	TotalAmt
Program Services	$773,695	ProgramServicesAmt
Management And General	$115,610	ManagementAndGeneralAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$1,390,067	TotalAmt
Program Services	$1,182,456	ProgramServicesAmt
Management And General	$207,611	ManagementAndGeneralAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$203,970	TotalAmt
Program Services	$63,314	ProgramServicesAmt
Management And General	$140,656	ManagementAndGeneralAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
MEDICAL SUPPLIES	$3,394,018	$3,295,310	$98,708	$0
PATIENT COSTS	$593,883	$593,883	$0	$0
RESEARCH PARTICIPANTS E	$234,768	$234,286	$482	$0
OTHER PURCHASED SERVICE	$226,020	$85,438	$140,582	$0

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	$83,025	TotalAmt
Management And General	$83,025	ManagementAndGeneralAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$87,516,122	TotalAmt
Program Services	$73,646,780	ProgramServicesAmt
Management And General	$13,869,342	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$8,265,497	BOYAmt
EOY	$4,930,235	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$1,478,988	BOYAmt
EOY	$1,603,243	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$8,245,451	BOYAmt
EOY	$10,949,904	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$984,414	BOYAmt
EOY	$358,536	EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

Field	Value	IRS element (for citing)
EOY	$0	EOYAmt

Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp

Field	Value	IRS element (for citing)
EOY	$0	EOYAmt

Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp

Field	Value	IRS element (for citing)
EOY	$0	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
EOY	$0	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$937,229	BOYAmt
EOY	$996,445	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$31,629,991	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$3,732,240	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$28,627,035	BOYAmt
EOY	$27,897,751	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$11,284,790	BOYAmt
EOY	$12,095,276	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
BOY	$33,041,866	BOYAmt
EOY	$35,963,558	EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

Field	Value	IRS element (for citing)
EOY	$0	EOYAmt

Intangible Assets IntangibleAssetsGrp

Field	Value	IRS element (for citing)
EOY	$0	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$1,489,093	BOYAmt
EOY	$1,243,134	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$94,354,363	BOYAmt
EOY	$96,038,082	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$6,437,799	BOYAmt
EOY	$6,125,525	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
EOY	$0	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$6,319,599	BOYAmt
EOY	$4,908,061	EOYAmt

Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$28,272,047	BOYAmt
EOY	$27,524,602	EOYAmt

Escrow Account Liability EscrowAccountLiabilityGrp

Field	Value	IRS element (for citing)
EOY	$0	EOYAmt

Loans From Officers Directors LoansFromOfficersDirectorsGrp

Field	Value	IRS element (for citing)
EOY	$0	EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

Field	Value	IRS element (for citing)
EOY	$0	EOYAmt

Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp

Field	Value	IRS element (for citing)
EOY	$0	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$1,706,233	BOYAmt
EOY	$1,771,209	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$42,735,678	BOYAmt
EOY	$40,329,397	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows FASB117	Yes (X)	OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$16,899,685	BOYAmt
EOY	$17,770,685	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$34,719,000	BOYAmt
EOY	$37,938,000	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$51,618,685	BOYAmt
EOY	$55,708,685	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$94,354,363	BOYAmt
EOY	$96,038,082	EOYAmt

Field	Value	IRS element (for citing)
Reconcilation Revenue Expnss	$6,063,124	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	-$1,973,124	NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets	$0	OtherChangesInNetAssetsAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	0	AccountantCompileOrReviewInd
FS Audited	Yes (1)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Consolidated Basis Fincl Stmt	Yes (X)	ConsolidatedBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (1)	AuditCommitteeInd
Federal Grant Audit Required	Yes (1)	FederalGrantAuditRequiredInd
Federal Grant Audit Performed	Yes (1)	FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Medical Research Organization	Yes (X)	MedicalResearchOrganizationInd

Hospital Name And Address HospitalNameAndAddressGrp

Supported Organization Name SupportedOrganizationName

Field	Value	IRS element (for citing)
Business Name Line1	VIRGINIA MASON MEDICAL CENTER	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
City	SEATTLE	CityNm
State Abbreviation	WA	StateAbbreviationCd

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$60,664,155	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$34,152,956	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$78,966,994	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$75,771,314	CurrentTaxYearMinus1YearAmt
Current Tax Year	$87,693,245	CurrentTaxYearAmt
Total	$337,248,664	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$60,664,155	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$34,152,956	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$78,966,994	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$75,771,314	CurrentTaxYearMinus1YearAmt
Current Tax Year	$87,693,245	CurrentTaxYearAmt
Total	$337,248,664	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$24,183,121	SubstantialContributorsTotAmt
Public Support Total170	$313,065,543	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$1,174,418	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$525,133	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$8,844,594	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$929,807	CurrentTaxYearMinus1YearAmt
Current Tax Year	$1,115,046	CurrentTaxYearAmt
Total	$12,588,998	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$6,105,766	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$3,157,242	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$5,286,187	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$5,702,614	CurrentTaxYearMinus1YearAmt
Current Tax Year	$4,770,955	CurrentTaxYearAmt
Total	$25,022,764	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$374,860,426	TotalSupportAmt
Public Support CY170	0.83520	PublicSupportCY170Pct
Public Support PY170	0.82020	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME:	FormAndLineReferenceDesc
Explanation	CLINICAL RESEARCH PROGRAM REVENUE - 2019 AMOUNT: $ 5,569,393. 2020 AMOUNT: $ 2,665,138. 2021 AMOUNT: $ 4,732,659. 2022 AMOUNT: $ 4,631,252. 2023 AMOUNT: $ 4,450,908. COLLABORATIVE RESEARCH AGREEMENT PROJECTS - EXTERNAL CORE INCOME - 2019 AMOUNT: $ 430,308. 2020 AMOUNT: $ 394,817. 2021 AMOUNT: $ 553,528. 2022 AMOUNT: $ 1,071,362. 2023 AMOUNT: $ 320,047. MISCELLANEOUS INCOME - 2019 AMOUNT: $ 106,065. 2020 AMOUNT: $ 97,287.	ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Organization Belongs Afflt Grp	Yes (X)	OrganizationBelongsAffltGrpInd

Total Grassroots Lobbying TotalGrassrootsLobbyingGrp

Field	Value	IRS element (for citing)
Affiliated Group Total	$157,006	AffiliatedGroupTotalAmt

Total Direct Lobbying TotalDirectLobbyingGrp

Field	Value	IRS element (for citing)
Affiliated Group Total	$12,373	AffiliatedGroupTotalAmt

Total Lobbying Expend TotalLobbyingExpendGrp

Field	Value	IRS element (for citing)
Affiliated Group Total	$169,379	AffiliatedGroupTotalAmt

Other Exempt Purpose Expend OtherExemptPurposeExpendGrp

Field	Value	IRS element (for citing)
Affiliated Group Total	$1,277,668,784	AffiliatedGroupTotalAmt

Total Exempt Purpose Expend TotalExemptPurposeExpendGrp

Field	Value	IRS element (for citing)
Affiliated Group Total	$1,277,838,163	AffiliatedGroupTotalAmt

Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp

Field	Value	IRS element (for citing)
Affiliated Group Total	$1,000,000	AffiliatedGroupTotalAmt

Grassroots Nontaxable GrassrootsNontaxableGrp

Field	Value	IRS element (for citing)
Affiliated Group Total	$250,000	AffiliatedGroupTotalAmt

Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp

Field	Value	IRS element (for citing)
Affiliated Group Total	$0	AffiliatedGroupTotalAmt

Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp

Field	Value	IRS element (for citing)
Affiliated Group Total	$0	AffiliatedGroupTotalAmt

Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$1,000,000	CurrentYearMinus3Amt
Current Year Minus2	$1,000,000	CurrentYearMinus2Amt
Current Year Minus1	$1,000,000	CurrentYearMinus1Amt
Current Year	$1,000,000	CurrentYearAmt
Total	$4,000,000	TotalAmt

Field	Value	IRS element (for citing)
Lobbying Ceiling	$6,000,000	LobbyingCeilingAmt

Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$205,420	CurrentYearMinus3Amt
Current Year Minus2	$219,020	CurrentYearMinus2Amt
Current Year Minus1	$153,865	CurrentYearMinus1Amt
Current Year	$169,379	CurrentYearAmt
Total	$747,684	TotalAmt

Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$1,000,000	CurrentYearMinus3Amt
Current Year Minus2	$250,000	CurrentYearMinus2Amt
Current Year Minus1	$250,000	CurrentYearMinus1Amt
Current Year	$250,000	CurrentYearAmt
Total	$1,750,000	TotalAmt

Field	Value	IRS element (for citing)
Grassroots Ceiling	$2,625,000	GrassrootsCeilingAmt

Avg Grassroots Lobbying Expend AvgGrassrootsLobbyingExpendGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$126,542	CurrentYearMinus3Amt
Current Year Minus2	$203,020	CurrentYearMinus2Amt
Current Year Minus1	$142,625	CurrentYearMinus1Amt
Current Year	$157,006	CurrentYearAmt
Total	$629,193	TotalAmt

Schedule D IRS990ScheduleD

Field	Value	IRS element (for citing)
Incl Escrow Custodial Acct Liab	0	InclEscrowCustodialAcctLiabInd
Endowments Held Unrelated Org	Yes (1)	EndowmentsHeldUnrelatedOrgInd

Land LandGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$14,110,000	OtherCostOrOtherBasisAmt
Book Value	$14,110,000	BookValueAmt

Buildings BuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$12,362,749	OtherCostOrOtherBasisAmt
Depreciation	$1,219,375	DepreciationAmt
Book Value	$11,143,374	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$4,912,695	OtherCostOrOtherBasisAmt
Depreciation	$2,512,865	DepreciationAmt
Book Value	$2,399,830	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$244,547	OtherCostOrOtherBasisAmt
Book Value	$244,547	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$27,897,751	TotalBookValueLandBuildingsAmt

Other Securities OtherSecuritiesGrp

Field	Value	IRS element (for citing)
Desc	INTEREST IN NET ASSETS OF VIRGINIA MASON MEDICAL CENTER	Desc
Book Value	$35,963,558	BookValueAmt
Method Valuation	F	MethodValuationCd

Field	Value	IRS element (for citing)
Total Book Value Securities	$35,963,558	TotalBookValueSecuritiesAmt

Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)

DescDesc	AmtAmt
LEASE LIABILITY (RELATES TO RIGHT-OF-USE ASSET)	$1,354,084
DUE TO RELATED PARTIES	$417,125

Field	Value	IRS element (for citing)
Total Liability	$1,771,209	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART X, LINE 2:	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON'S FINANCIAL INFORMATION IS INCLUDED IN COMMONSPIRIT HEALTH'S CONSOLIDATED AUDITED FINANCIAL STATEMENTS, WHICH INCLUDES THE FOLLOWING DISCLOSURE: COMMONSPIRIT REVIEWS ITS TAX POSITIONS QUARTERLY AND HAS DETERMINED THAT THERE ARE NO MATERIAL UNCERTAIN TAX POSITIONS THAT REQUIRE RECOGNITION IN THE ACCOMPANYING CONSOLIDATED FINANCIAL STATEMENTS.
PART X, LINE 1	IN ACCORDANCE WITH ASC TOPIC 842 LEASES, THE RESEARCH INSTITUTE ADOPTED THE LEASE STANDARD AND RECORDED LEASE LIABILITIES OVER THE LEASE TERMS BETWEEN 3 AND 10 YEARS. THE LEASES ARE PRIMARILY FOR REAL ESTATE, INCLUDING OFF-CAMPUS OUTPATIENT FACILITIES, MEDICAL OFFICE BUILDINGS, AND CORPORATE AND ADMINISTRATIVE OFFICES.
PART V ENDOWMENT FUNDS	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON'S (BRI) SOLE CORPORATE MEMBER IS VIRGINIA MASON FRANCISCAN HEALTH (VMFH). VMFH IS A SUPPORTING ORGANIZATION OF BRI AND VIRGINIA MASON MEDICAL CENTER (VMMC). VMMC HOLDS ENDOWMENT FUNDS THAT SUPPORT BRI RESEARCH AIMED AT DIABETES, RHEUMATOLOGY, IMMUNOLOGY, AND OTHER RESEARCH. THE BALANCE OF THESE ENDOWMENTS WAS $33.0 MILLION AND $36.0 MILLION ON JUNE 30, 2023 AND JUNE 30, 2024, RESPECTIVELY.

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (2 entries)

RegionRegionTxt	OfficesOfficesCnt	EmployeeEmployeeCnt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
EUROPE (INCLUDING ICELAND AND GREENLAND)	0	0	GRANT	MEDICAL RESEARCH	$1,738,204
NORTH AMERICA	0	0	GRANT	MEDICAL RESEARCH	$103,040

Field	Value	IRS element (for citing)
Subtotal Offices	0	SubtotalOfficesCnt
Subtotal Employees	0	SubtotalEmployeesCnt
Continuation Total Office	0	ContinuationTotalOfficeCnt
Continuation Total Employee	0	ContinuationTotalEmployeeCnt
Total Office	0	TotalOfficeCnt
Total Employee	0	TotalEmployeeCnt
Subtotal Spent	$1,841,244	SubtotalSpentAmt
Continuation Spent	$0	ContinuationSpentAmt
Total Spent	$1,841,244	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (5 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt	Non Cash AssistanceNonCashAssistanceAmt
EUROPE (INCLUDING ICELAND AND GREENLAND)	GENERAL SUPPORT	$72,244	WIRE TRANSFER	$0
EUROPE (INCLUDING ICELAND AND GREENLAND)	GENERAL SUPPORT	$1,543,197	WIRE TRANSFER	$0
EUROPE (INCLUDING ICELAND AND GREENLAND)	GENERAL SUPPORT	$115,311	WIRE TRANSFER	$0
EUROPE (INCLUDING ICELAND AND GREENLAND)	GENERAL SUPPORT	$7,452	WIRE TRANSFER	$0
NORTH AMERICA	GENERAL SUPPORT	$103,040	WIRE TRANSFER	$0

Field	Value	IRS element (for citing)
Total501c3 Org	0	Total501c3OrgCnt
Total Other Org	5	TotalOtherOrgCnt
Transfer To Foreign Corp	0	TransferToForeignCorpInd
Interest In Foreign Trust	0	InterestInForeignTrustInd
Foreign Corp Ownership	0	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	0	PassiveForeignInvestmestCoInd
Foreign Partnership	0	ForeignPartnershipInd
Boycott Countries	0	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART I, LINE 2: SUB-RECIPIENT MONITORING POLICY -MEDICAL RESEARCH SUB AWARD	BRI HAS FORMAL POLICIES AND PRODECURES TO ASSURE FULL COMPLIANCE WITH APPLICABLE POLICIES AND LAWS GOVERNING FEDERAL GRANTS. THE SUB-RECIPIENT MONITORING POLICY PROVIDES ASSURANCE THAT SUB-RECIPIENTS COMPLY WITH FEDERAL GRANT REGULATIONS. THIS POLICY SETS THE CRITERIA TO ESTABLISH ELIGIBILITY OF SUB-RECIPIENTS TO PROVIDE ANNUAL AUDITED FINANCIAL REPORTS AND THE ANNUAL OMB SINGLE AUDIT REPORT THAT IDENTIFY COMPLIANCE WITH FEDERAL LAWS AND REGULATIONS. THE REPORTS ARE ANALYZED WITH EMPHASIS ON AUDITOR'S ASSESSMENT OF SUB-RECIPIENT INTERNAL CONTROLS AND A STANDARDIZED RISK ASSESSMENT IS PRESENTED TO MANAGEMENT ON EACH SUB-RECIPIENT. A MANAGEMENT LETTER IS ISSUED TO EACH SUB-RECIPIENT SHOWING ANY FINDINGS ON THEIR OMB SINGLE AUDIT REPORT, AND MEASUREMENTS ARE SET FOR INCREASED MONITORING WHEN AN ELEVATED LEVEL OF RISK IS ESTABLISHED. MANAGEMENT HAS COMMUICATED WITH AN EDUCATED ADMINISTRATIVE STAFF REGARDING IMPLEMENTATION OF THIS POLICY. THE DIRECTOR OF GRANTS AND CONTRACTS IS RESPONSIBILE FOR MONITORING SUB-RECIPIENT ADHERENCE TO FINANCIAL REGULATIONS. THE PRINCIPAL INVESTIGATOR IS RESPONSIBLE FOR OVERSEEING THE SATISFACTORY PERFORMANCE OF THE SUB-AWARD TO ENSURE THAT GOALS ARE ACHIEVED. IF THERE ARE UNUSUAL OR UNFORESEEN ITEMS, THESE WILL BE INVESTIGATED.
PART 1, LINE 3F	THE EXPENDITURES WERE ACTUAL EXPENSES INCURRED IN THE REGION BASED ON INDIVIDUAL EXPENSE REPORTS AND TRACKING OF EXPENDITURES BY GRANT OR DEPARTMENT ON THE ACCRUAL BASIS OF ACCOUNTING.
PART II, LINE 1	THE EXPENDITURES WERE EXPENSES INCURRED IN THE REGION BASED ON AWARD GOALS ON THE ACCRUAL BASIS OF ACCOUNTING.

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (80 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	Cash GrantCashGrantAmt	Non Cash AssistanceNonCashAssistanceAmt	Purpose Of GrantPurposeOfGrantTxt	IRC SectionIRCSectionDesc	Address Line2USAddress/AddressLine2Txt
ADVARRA INC
PO BOX 74008070	CHICAGO	IL	606748070	311358981	$357,835	$0	MEDICAL FND SUPPORT
ALLEN INSTITUTE
615 WESTLAKE AVE N	SEATTLE	WA	981094307	912155317	$172,923	$0	MEDICAL FND SUPPORT	501C3
ARKANSAS CHILDREN'S RESEARCH INSTITUTE
ONE CHILDRENS WAY FINANCIAL SVCS	LITTLE ROCK	AR	722023591	710694931	$39,424	$0	MEDICAL FND SUPPORT	509C3	SLOT 663
AZENTA LIFE SCIENCES
PO BOX 3865	CAROL STEAM	IL	601323865	200628587	$2,405,904	$0	MEDICAL FND SUPPORT	501C3
BAYLOR COLLEGE OF MEDICINE
ONE BAYLOR PLAZA SUITE 600-D	HOUSTON	TX	770303411	741613878	$5,767	$0	MEDICAL FND SUPPORT	501C3
BRIGHAM AND WOMEN'S HOSPITAL
BANK OF AMERICA NA PO BOX 3887	BOSTON	MA	022413887	042312909	$1,246,280	$0	MEDICAL FND SUPPORT	501C3
CEDARS-SINAI MEDICAL CENTER
6500 WILSHIRE BLVD SUITE 1150	LOS ANGELES	CA	90048	951644600	$80,327	$0	MEDICAL FND SUPPORT	501C3
CHILDREN'S HOSPITAL OF PHILADELPHIA
PO BOX 8550 LOCKBOX 1457	PHLILADELPHIA	PA	191781457	231352166	$24,924	$0	MEDICAL FND SUPPORT	501C3
CHILDREN'S MERCY HOSPITAL
2401 GILLHAM ROAD	KANSAS CITY	MO	64101	440605373	$20,563	$0	MEDICAL FND SUPPORT	501C3
DANA-FARBER CANCER INSTITUTE INC
450 BROOKLINE AVE	BOSTON	MA	02215	042263040	$176,786	$0	MEDICAL FND SUPPORT	501C3
DUKE UNIVERSITY
PO BOX 602651	CHARLOTTE	NC	282602651	560532129	$1,356,466	$0	MEDICAL FND SUPPORT	501C3
EMORY UNIVERSITY
PO BOX 935084	ATLANTA	GA	311935084	580566256	$819,807	$0	MEDICAL FND SUPPORT	501C3
FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
350 COMMUNITY DRIVE	MANHASSET	NY	11030	112673595	$383,602	$0	MEDICAL FND SUPPORT	501C3
FRED HUTCHINSON CANCER CENTER
1100 FAIRVIEW AVE NMAILSTOP J6-330	SEATTLE	WA	98109	911935159	$430,065	$0	MEDICAL FND SUPPORT	501C3
GEORGETOWN UNIVERSITY
2121 WISCONSIN AVE NW SUITE 400	WASHINGTON	DC	20007	530196603	$9,784	$0	MEDICAL FND SUPPORT	501C3
HENRY FORD HEALTH SYSTEM
1 FORD PLACE	DETROIT	MI	48202	381357020	$65,638	$0	MEDICAL FND SUPPORT	501C3
HOSPITAL FOR SPECIAL SURGERY
535 EAST 70TH STREET	NEW YORK	NY	10021	131624135	$97,909	$0	MEDICAL FND SUPPORT	501C3
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
ONE GUSTAVE L LEVY PLACE BOX 3500	NEW YORK	NY	100296574	136171197	$2,351,860	$0	MEDICAL FND SUPPORT	501C3
IHC HEALTH SERVICES INC
36 SOUTH STATE STREET SUITE 2200	SALT LAKE CITY	UT	84111	942854057	$64,794	$0	MEDICAL FND SUPPORT
INDIANA UNIVERSITY
620 UNION DRIVE ROOM 618	INDIANAPOLIS	IN	462025167	356001673	$107,074	$0	MEDICAL FND SUPPORT	501C3
INFINITY BIOLOGIX LLC
30 KNIGHTSBRIDGE ROAD BUILDING 3	PISCATAWAY	NJ	08854	845054901	$940,742	$0	MEDICAL FND SUPPORT
JOHNS HOPKINS UNIVERSITY
12529 COLLECTIONS CENTER DRIVE	CHICAGO	IL	60693	520595110	$4,770,126	$0	MEDICAL FND SUPPORT	501C3
JOSLIN DIABETES CENTER
ONE JOSLIN PLACE	BOSTON	MA	022155306	042203836	$46,609	$0	MEDICAL FND SUPPORT	501C3
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT H
1124 W CARSON STREET	TORRANCE	CA	905022006	952138184	$18,916	$0	MEDICAL FND SUPPORT	501C3
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STREET	BOSTON	MA	02114	042697983	$457,152	$0	MEDICAL FND SUPPORT	501C3
MAYO CLINIC
200 FIRST STREET SOUTHWEST	ROCHESTER	MN	55905	416011702	$117,511	$0	MEDICAL FND SUPPORT	501C3
MAYO CLINIC JACKSONVILLE
4500 SAN PABLO ROAD	JACKSONVILLE	FL	32224	593337028	$23,396	$0	MEDICAL FND SUPPORT	501C3
MEDICAL UNIVERSITY OF SOUTH CAROLINA
1 SOUTH PARK CIRCLE BLDG 1 STE 506	CHARLESTON	SC	29407	576000722	$43,133	$0	MEDICAL FND SUPPORT	501C3
MY OWN MED INC
4825 ESSEX AVENUE	CHEVY CHASE	MD	20815	462108432	$18,200	$0	MEDICAL FND SUPPORT	501C3
NEW YORK UNIVERSITY-SCHOOL OF MEDICINE
PO BOX 415026	BOSTON	MA	022415026	135562308	$1,478,317	$0	MEDICAL FND SUPPORT	501C3
NORTH SHORE UNIVERSITY HEALTH SYSTEM
1001 UNIVERSITY PLACE	EVANSTON	IL	60201	362167060	$24,124	$0	MEDICAL FND SUPPORT	501C3
NORTHWESTERN UNIVERSITY
633 CLARK ROOM G547	EVANSTON	IL	60208	362167817	$218,854	$0	MEDICAL FND SUPPORT	501C3
OHIO STATE UNIVERSITY
1960 KENNY ROAD	COLUMBUS	OH	43210	316025986	$67,962	$0	MEDICAL FND SUPPORT	501C3
OHSU-PATIENT BUSINESS SVC
PO BOX 3595	PORTLAND	OR	97207	931176109	$271,513	$0	MEDICAL FND SUPPORT	501C3
OKLAHOMA MEDICAL RESEARCH FOUNDATION
825 NE 13TH STREET	OKLAHOMA CITY	OK	73104	730580274	$28,714	$0	MEDICAL FND SUPPORT	501C3
PENN STATE UNIVERSITY
500 UNIVERSITY DRIVE	HERSHEY	PA	17033	246000376	$53,468	$0	MEDICAL FND SUPPORT	501C3
REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE
228 ALDRICH HALL	IRVINE	CA	926971050	952226406	$10,506	$0	MEDICAL FND SUPPORT	501C3
REGENTS OF THE UNIVERSITY OF COLORADO
PO BOX 910238	AURORA	CO	80045	846000555	$608,360	$0	MEDICAL FND SUPPORT	501C3
RESEARCH FOUNDATION OF SUNY
35 STATE STREET	ALBANY	NY	122072826	141368361	$29,539	$0	MEDICAL FND SUPPORT	501C3
RHO FEDERAL SYSTEMS DIVISION INC
2635 E NC HWY 54	DURHAM	NC	27713	561927659	$821,731	$0	MEDICAL FND SUPPORT
ROCHESTER GENERAL HOSPITAL
1425 PORTLAND AVE	ROCHESTER	NY	14621	160743134	$40,000	$0	MEDICAL FND SUPPORT	501C3
SANFORD RESEARCH
2301 E 60TH ST	SIOUX FALLS	SD	57104	460450378	$32,109	$0	MEDICAL FND SUPPORT	501C3
SARAH CANNON RESEARCH INSTITUTE LLC
1100 DR MARTIN L KING JR BLVD SUITE	NASHVILLE	TN	37203	201557751	$7,145	$0	MEDICAL FND SUPPORT		800
SEATTLE CHILDREN'S HOSPITAL RESEARCH INSTITUTE
818 STEWART 3RD FLOOR	SEATTLE	WA	981240728	910564748	$982,925	$0	MEDICAL FND SUPPORT	501C3
STANFORD UNIVERSITY
PO BOX 884253	LOS ANGELES	CA	900884253	941156365	$699,007	$0	MEDICAL FND SUPPORT	501C3
SWEDISH HEALTH SERVICES - GRANTS
SWEDISH HEALTH SERVICES PO BOX	SEATTLE	WA	981249845	910433740	$28,150	$0	MEDICAL FND SUPPORT	501C3	35143 LB 1129
TEMPLE UNIVERSITY
1852 N 10TH STREET	PHILADELPHIA	PA	19122	231365971	$24,378	$0	MEDICAL FND SUPPORT	501C3
THE CLEVELAND CLINIC FOUNDATION
PO BOX 931562	CLEVELAND	OH	44193	340714585	$469,757	$0	MEDICAL FND SUPPORT	501C3
THE MEDICAL COLLEGE OF WISCONSIN INC
8701 WATERTOWN PLANK RD	MILWAUKEE	WI	53226	390806261	$30,584	$0	MEDICAL FND SUPPORT	501C3
THE REGENTS UNIVERSITY CALIFORNIA SANDIEGO
UCSD CAMPUS MAIN DEPOSITORY PO BOX	LOS ANGELES	CA	900741539	956006144	$346,345	$0	MEDICAL FND SUPPORT	501C3	741539
THE UNIV OF TEXAS SOUTHWESTERN MEDICAL CENTER
LOCK BOX 845477	DALLAS	TX	75284	756002868	$72,505	$0	MEDICAL FND SUPPORT	501C3
THE UNIVERSITY OF CHICAGO
401 N MICHIGAN AVE 9TH FLOOR	CHICAGO	IL	60611	362177139	$49,047	$0	MEDICAL FND SUPPORT	501C3
TRUSTEES OF COLUMBIA UNIVERSITY
1150 SAINT NICOLAS AVE	NEW YORK	NY	10032	135598093	$129,085	$0	MEDICAL FND SUPPORT	501C3
TUFTS MEDICAL CENTER
800 WASHINGTON STREET	BOSTON	MA	02111	043400617	$43,922	$0	MEDICAL FND SUPPORT	501C3
UNIV OF MINNESOTA REGENTS
NW 5957	MINNEAPOLIS	MN	554855957	416007513	$117,983	$0	MEDICAL FND SUPPORT	501C3
UNIV OF NEBRASKA MEDICAL CENTER
987835 NEBRASKA MEDICAL CENTER	OMAHA	NE	681987835	470049123	$32,309	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF ALABAMA AT BIRMINGHAM
1720 2ND AVENUE SOUTH	BIRMINGHAM	AL	35294	636005396	$63,979	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF CALIFORNIA LOS ANGELES
757 WESTWOOD PLAZA SUITE 1119	LOS ANGELES	CA	900957495	956006143	$59,602	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
UCSF MAIN DEPOSITORY PO BOX 748872	LOS ANGELES	CA	900744872	946036493	$8,492,043	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF CALIFORNIA DAVIS
UC DAVIS AR LOCKBOX PO BOX 741816	LOS ANGELES	CA	900741816	946036494	$72,294	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF CINCINNATI
UNIVERSITY HALL SUITE 530	CINCINNATI	OH	45221	316000989	$23,774	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF COLORADO DENVER - BARBARA DAVIS CTR
1775 AURORA CT B-140	AURORA	CO	80045	846000555	$5,135	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF IOWA
2 GILMORE HALL	IOWA CITY	IA	52242	426004813	$130,397	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF MARYLAND BALTIMORE
PO BOX 41428	BALTIMORE	MD	212036428	526002033	$74,048	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF MASSACHUSETTS WORCESTER
55 LAKE AVENUE NORTH	WORCESTER	MA	016550002	043167352	$160,625	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF MIAMI
PO BOX 405803	ATLANTA	GA	303845803	590624458	$34,344	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF MICHIGAN
BOX 223131	PITTSBURGH	PA	152512131	386006309	$472,336	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF MISSOURI
118 UNIVERSITY HALL	COLUMBIA	MO	65211	436003859	$26,915	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
PO BOX 402420	ATLANTA	GA	303842420	566001393	$347,423	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF PENNSYLVANIA
PO BOX 785541	PHILADELPHIA	PA	191785541	231352685	$580,943	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF PITTSBURGH
ATTN XXX-XX-XXXX ROSS STREET 154-0455	PITTSBURGH	PA	152620001	250965591	$349,824	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF SOUTH FLORIDA
4202 E FOWLER AVE	TAMPA	FL	33620	593102112	$51,061	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF TEXAS HEALTH CENTER HOUSTON
7000 FANNIN ST	HOUSTON	TX	770305400	741761309	$12,230	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF TEXAS MD ANDERSON CANCER CTR
PO BOX 4390 GRANTS CONTRACT ACCTNG	HOUSTON	TX	772104390	746001118	$5,858	$0	MEDICAL FND SUPPORT	501C3	202
UNIVERSITY OF WA GRANTS & CONTRACTS
12455 COLLECTIONS DRIVE	CHICAGO	IL	606930001	916001537	$393,527	$0	MEDICAL FND SUPPORT	501C3
UNIVERSITY OF WISCONSIN MADISON BOARD OF REGENTS
600 HIGHLAND AVE	MADISON	WI	53792	396006492	$167,514	$0	MEDICAL FND SUPPORT	501C3
VANDERBILT UNIVERSITY MED CTR
PO BOX 121236	DALLAS	TX	753121236	620476822	$43,750	$0	MEDICAL FND SUPPORT	501C3
VIRGINIA COMMONWEALTH UNIVERSITY
GRANTS AND CONTRACTS ACCOUNTING BOX	RICHMOND	VA	23284	546001758	$108,637	$0	MEDICAL FND SUPPORT	501C3	843039
WASHINGTON UNIVERSITY IN ST LOUIS
7425 FORSYTHE	ST LOUIS	MO	63105	460653611	$746,777	$0	MEDICAL FND SUPPORT	501C3
YALE UNIVERSITY
PO BOX 1873	NEW HAVEN	CT	065081873	060646973	$187,561	$0	MEDICAL FND SUPPORT	501C3

Field	Value	IRS element (for citing)
Total501c3 Org	75	Total501c3OrgCnt
Total Other Org	5	TotalOtherOrgCnt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 2: SUB-RECIPIENT MONITORING POLICY -MEDICAL RESEARCH SUB AWARD	FormAndLineReferenceDesc
Explanation	BRI HAS FORMAL POLICIES AND PRODECURES TO ASSURE FULL COMPLIANCE WITH APPLICABLE POLICIES AND LAWS GOVERNING FEDERAL GRANTS. THE SUB-RECIPIENT MONITORING POLICY PROVIDES ASSURANCE THAT SUB-RECIPIENTS COMPLY WITH FEDERAL GRANT REGULATIONS. THIS POLICY SETS THE CRITERIA TO ESTABLISH ELIGIBILITY OF SUB-RECIPIENTS TO PROVIDE ANNUAL AUDITED FINANCIAL REPORTS AND THE ANNUAL OMB SINGLE AUDIT REPORT THAT IDENTIFY COMPLIANCE WITH FEDERAL LAWS AND REGULATIONS. THE REPORTS ARE ANALYZED WITH EMPHASIS ON AUDITOR'S ASSESSMENT OF SUB-RECIPIENT INTERNAL CONTROLS AND A STANDARDIZED RISK ASSESSMENT IS PRESENTED TO MANAGEMENT ON EACH SUB-RECIPIENT. A MANAGEMENT LETTER IS ISSUED TO EACH SUB-RECIPIENT SHOWING ANY FINDINGS ON THEIR OMB SINGLE AUDIT REPORT, AND MEASUREMENTS ARE SET FOR INCREASED MONITORING WHEN AN ELEVATED LEVEL OF RISK IS ESTABLISHED. MANAGEMENT HAS COMMUICATED WITH AN EDUCATED ADMINISTRATIVE STAFF REGARDING IMPLEMENTATION OF THIS POLICY. THE DIRECTOR OF GRANTS AND CONTRACTS IS RESPONSIBILE FOR MONITORING SUB-RECIPIENT ADHERENCE TO FINANCIAL REGULATIONS. THE PRINCIPAL INVESTIGATOR IS RESPONSIBLE FOR OVERSEEING THE SATISFACTORY PERFORMANCE OF THE SUB-AWARD TO ENSURE THAT GOALS ARE ACHIEVED. IF THERE ARE UNUSUAL OR UNFORESEEN ITEMS, THESE WILL BE INVESTIGATED.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	0	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	Yes (1)	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	0	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	0	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	0	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	0	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	0	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	0	AnyNonFixedPaymentsInd
Initial Contract Exception	0	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (9 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
KETUL PATEL
CHIEF EXECUTIVE OFFICER VMFH	$1,393,552	$0	$959,840	$0	$259,995	$0	$19,350	$0	$13,553	$0	$2,646,290	$0	$0	$0
JANE BUCKNER MD
PRESIDENT	$501,678	$0	$0	$0	$0	$0	$30,000	$0	$2,412	$0	$534,090	$0	$0	$0
MARGARET MCCORMICK PHD
EXECUTIVE DIRECTOR & COO	$303,699	$0	$0	$0	$0	$0	$30,000	$0	$5,478	$0	$339,177	$0	$0	$0
WILLIAM KWOK PHD
RESEARCH MEMBER	$285,671	$0	$800	$0	$0	$0	$30,000	$0	$3,612	$0	$320,083	$0	$0	$0
DANIEL CAMPBELL PHD
DIRECTOR, CENTER FOR FUNDAMENTAL IMM	$228,955	$0	$1,400	$0	$0	$0	$15,219	$0	$5,400	$0	$250,974	$0	$0	$0
JESSICA HAMERMAN PHD
DIRECTOR, ACADEMIC AFFAIRS	$227,626	$0	$1,400	$0	$0	$0	$11,701	$0	$6,804	$0	$247,531	$0	$0	$0
CARMEN MIKACENIC MD
ASSOCIATE RESEARCH MEMBER	$223,366	$0	$800	$0	$0	$0	$22,500	$0	$6,948	$0	$253,614	$0	$0	$0
PETER LINSLEY PHD
MEMBER, PRINCIPAL INVESTIGATOR	$219,611	$0	$800	$0	$0	$0	$30,000	$0	$3,924	$0	$254,335	$0	$0	$0
MICHAEL LABOSIER
CFO	$186,169	$0	$800	$0	$0	$0	$22,617	$0	$5,072	$0	$214,658	$0	$0	$0

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART I, LINE 3	DURING THE CALENDAR YEAR 2023, COMPENSATION FOR THE TOP MANAGEMENT OFFICIAL WAS ESTABLISHED BY COMMONSPIRIT HEALTH. COMMONSPIRIT HEALTH USED ONE OR MORE OF THE METHODS DESCRIBED IN SCHEDULE J, PART I, LINE TO ESTABLISH THE TOP MANAGEMENT OFFICIAL'S COMPENSATION: (1) COMPENSATION COMMITTEE; (2) INDEPENDENT COMPENSATION CONSULTANT; (3) COMPENSATION SURVEY OR STUDY; (4) APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE. SEE SCHEDULE O DISCLOSURE FOR FORM 990, PART VI, SECTION B, LINE 15 FOR ADDITIONAL INFORMATION.
PART I, LINE 4B	CERTAIN REPORTABLE INDIVIDUALS ARE COVERED BY AN EXECUTIVE SEVERANCE POLICY THAT PROVIDES MARKET-STANDARD COMPENSATION, RANGING FROM PAYMENTS OF 9 MONTHS TO 2 YEARS OF BASE COMPENSATION, DEPENDING ON THE EXECUTIVE'S POSITION, IN THE EVENT OF A POSITION ELIMINATION OR OTHER INVOLUNTARY TERMINATION, IN ACCORDANCE WITH THE GUIDELINES OF THE POLICY. DURING THE 2023 CALENDAR YEAR, COMMONSPIRIT HEALTH ("COMMONSPIRIT") MAINTAINED A SUPPLEMENTAL NON-QUALIFIED DEFERRED COMPENSATION PLAN FOR DIVISION CEOS/PRESIDENTS AND OTHER DESIGNATED COMMONSPIRIT EXECUTIVES AT THE LEVEL OF SENIOR VICE PRESIDENT AND ABOVE. DUE TO THE "SUPER" VESTING RULES UNDER COMMONSPIRIT'S DEFERRED COMPENSATION PLAN, PARTICIPANTS WHO HAVE MET CERTAIN REQUIREMENTS SUCH AS INVOLUNTARY TERMINATION WITHOUT CAUSE, AGE, AGE AND YEARS OF SERVICE, OR MORE THAN 5 YEARS OF PLAN PARTICIPATION ARE ELIGIBLE TO RECEIVE THEIR 2023 CONTRIBUTIONS IN CASH. THESE CASH PAYOUTS ARE INCLUDED IN THE PARTICIPANT'S REPORTABLE COMPENSATION IN COLUMN (III) OTHER REPORTABLE COMPENSATION ON SCHEDULE J PART II. DURING 2023, THE FOLLOWING PAYMENTS WERE MADE PURSUANT TO THE SUPER VESTING RULES: KETUL J PATEL, $246,662.
SCHEDULE J, PART II:	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON FOLLOWS COMMONSPIRIT'S EXECUTIVE COMPENSATION PHILOSOPHY. COMMONSPIRIT'S EXECUTIVE COMPENSATION PHILOSOPHY IS DESIGNED TO ASSIST COMMONSPIRIT IN ATTRACTING AND RETAINING THE CALIBER OF EXECUTIVES REQUIRED TO ENABLE COMMONSPIRIT TO FULFILL ITS MISSION OF PROVIDING HIGH QUALITY HEALTHCARE FOR ALL PERSONS REGARDLESS OF THEIR ABILITY TO PAY FOR SERVICES, IMPROVING THE QUALITY OF LIFE IN THE COMMUNITIES COMMONSPIRIT SERVES, PROMOTING PATIENT AND EMPLOYEE SATISFACTION, AND ENSURING FINANCIAL STABILITY. A SUBSTANTIAL PORTION OF EXECUTIVE COMPENSATION IS PERFORMANCE BASED AND IS LINKED TO ORGANIZATIONAL GOALS APPROVED IN ADVANCE BY THE HUMAN RESOURCES AND COMPENSATION COMMITTEE. THESE GOALS INCLUDE ATTAINMENT OF ANNUAL AND LONG-TERM FINANCIAL PERFORMANCE, CERTAIN HEALTHCARE QUALITY STANDARDS AND COMMONSPIRIT'S COMMITMENT TO SERVING THE POOR AND DISENFRANCHISED IN THE COMMUNITIES IT SERVES. TOTAL COMPENSATION, WHICH INCLUDES BASE SALARY, ANNUAL, AND LONG-TERM INCENTIVE COMPENSATION, IS ESTABLISHED TO APPROXIMATE THE PREVAILING MARKET CONDITIONS FOR EXECUTIVES OF COMPANIES OF SIMILAR SIZE, REVENUES AND COMPLEXITY. PAYMENTS PURSUANT TO A LONG-TERM FINANCIAL PERFORMANCE GOAL WERE PAID IN CALENDAR YEAR 2023. KETUL PATEL WAS COMPENSATED BY COMMONSPIRIT HEALTH FOR HIS SERVICES TO BENAROYA RESEARCH INSTITUTE. FOR 990 PURPOSES, COMMONSPIRIT HEALTH IS AN UNRELATED ORGANIZATION, SO COMPENSATION HAS BEEN PRESENTED AS PAID BY BENAROYA RESEARCH INSTITUTE.

Schedule K IRS990ScheduleK

Tax Exempt Bonds Issues TaxExemptBondsIssuesGrp (2 entries)

Bond ReferenceBondReferenceCd	Bond Issuer EINBondIssuerEIN	CUSIPCUSIPNum	Bond IssuedBondIssuedDt	Issue PriceIssuePriceAmt	PurposePurposeDesc	DefeasedDefeasedInd	On Behalf Of IssuerOnBehalfOfIssuerInd	Pool FinancingPoolFinancingInd
WA ECON DEVEL FIN AUTH-2019 SERIES A
A	911493002	000000000	2019-02-26	$25,716,490	SEE PART VI	0	Yes (1)	0
WA ECON DEVEL FIN AUTH-2019 SERIES B
B	911493002	000000000	2019-02-26	$6,000,000	SEE PART VI	0	Yes (1)	0

Tax Exempt Bonds Proceeds TaxExemptBondsProceedsGrp (2 entries)

Bond ReferenceBondReferenceCd	RetiredRetiredAmt	Total ProceedsTotalProceedsAmt	Other Spent ProceedsOtherSpentProceedsAmt	Refunding Tax Exempt BondsRefundingTaxExemptBondsInd	Refunding Taxable BondsRefundingTaxableBondsInd	Final Allocation MadeFinalAllocationMadeInd	Adequate Books And Rec MaintAdequateBooksAndRecMaintInd	Capital ExpendituresCapitalExpendituresAmt	Substantial CompletionSubstantialCompletionYr
A	$3,503,018	$25,716,490	$25,716,490	Yes (1)	0	Yes (1)	Yes (1)
B	$452,789	$6,000,000		Yes (1)	0	Yes (1)	Yes (1)	$6,000,000	2022

Tax Exempt Bonds Private Bus Use TaxExemptBondsPrivateBusUseGrp (2 entries)

Bond ReferenceBondReferenceCd	Owning Bond Financed PropertyOwningBondFinancedPropertyInd	Any Lease ArrangementsAnyLeaseArrangementsInd	Mgmt Contract Bond Fincd PropMgmtContractBondFincdPropInd	Any Research AgreementsAnyResearchAgreementsInd	Engage Bond Counsel ResearchEngageBondCounselResearchInd	Private Bus Use By OthersPrivateBusUseByOthersPct	Total Private Business UseTotalPrivateBusinessUsePct	Bond Iss Meet Prvt Sec Pymt TestBondIssMeetPrvtSecPymtTestInd	Change In Use Bond Financed PropChangeInUseBondFinancedPropInd	Procs Nonqualified Bond RemdtdProcsNonqualifiedBondRemdtdInd
A	0	0	0	Yes (1)	Yes (1)	0.03840	0.03840	0	0	Yes (1)
B	0	0	0	Yes (1)	Yes (1)	0.03840	0.03840	0	0	Yes (1)

Tax Exempt Bonds Arbitrage TaxExemptBondsArbitrageGrp (2 entries)

Bond ReferenceBondReferenceCd	Form8038 T FiledForm8038TFiledInd	Rebate Not Due YetRebateNotDueYetInd	Exception To RebateExceptionToRebateInd	No Rebate DueNoRebateDueInd	Variable Rate IssueVariableRateIssueInd	Hedge Identified In Bks And RecHedgeIdentifiedInBksAndRecInd	Gross Proceeds Invested In GICGrossProceedsInvestedInGICInd	Gross Proceeds InvestedGrossProceedsInvestedInd	Written Proc To Monitor ReqsWrittenProcToMonitorReqsInd
A	0	Yes (1)	0	0	Yes (1)	0	0	0	Yes (1)
B	0	Yes (1)	0	0	Yes (1)	0	0	0	Yes (1)

Procedures Corrective Action ProceduresCorrectiveActionGrp (2 entries)

Bond ReferenceBondReferenceCd	Procedures Corrective ActionProceduresCorrectiveActionInd
A	Yes (1)
B	Yes (1)

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART 1, LINE A, COLUMN F PURPOSES:	TO REFUND WEDFA SERIES 2012 B BONDS ISSUED 06/01/2012, AND WEDFA SERIES 2016 BONDS ISSUED ON 06/01/2016.
PART 1, LINE B, COLUMN F PURPOSES:	TO FUND RESEARCH FACILITY IMPROVEMENTS AND EQUIPMENT PURCHASES ON A DRAW-DOWN BASIS OVER A THREE-YEAR PERIOD ENDING IN 2022.

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (10 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, PART III, LINE 4:	AT BRI, WE INTEGRATE THREE TYPES OF MEDICAL RESEARCH - LABORATORY RESEARCH, TRANSLATIONAL RESEARCH, AND CLINICAL RESEARCH - TO IMPROVE LIVES. ALL OUR SCIENTISTS COLLABORATE TO EXPLORE BASIC SCIENCE AS WELL AS CLINICAL APPLICATIONS, WHICH WE BELIEVE IS THE BEST WAY TO DESIGN STUDIES WITH THE HIGHEST POTENTIAL FOR SUCCESS. AT BRI, DISCOVERY STARTS IN THE LABORATORY BUT IS SPARKED BY THE NEEDS AND EXPERIENCES OF PATIENTS.
FORM 990, PART III, LINE 1:	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON (BRI) IS ONE OF THE FEW RESEARCH INSTITUTES IN THE WORLD DEVOTED TO FINDING CAUSES AND CURES FOR AUTOIMMUNE AND IMMUNE SYSTEM DISEASES, INCLUDING TYPE 1 DIABETES, MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS, LUPUS, INFLAMMATORY BOWEL DISEASE, CANCERS, ALLERGIES AND INFECTIOUS DISEASES. BRI IS AFFILIATED WITH COMMONSPIRIT HEALTH AND VIRGINIA MASON FRANCISCAN HEALTH, WHICH PROVIDES GOVERNANCE AND OVERSIGHT, AND THE VIRGINIA MASON FOUNDATION, WHICH PROVIDES DEVELOPMENT SUPPORT. BRI'S BOLD MISSION IS TO ADVANCE THE SCIENCE TO PREDICT, PREVENT, REVERSE AND CURE DISEASES OF THE IMMUNE SYSTEM TO ACHIEVE OUR VISION OF A HEALTHY IMMUNE SYSTEM FOR EVERYONE. BRI IS LED BY PRESIDENT JANE H. BUCKNER, MD, AND EXECUTIVE DIRECTOR/COO MARGARET MCCORMICK, PHD. DISCOVERIES AT BRI ARE ACCELERATED BY OUR TALENTED RESEARCHERS, COLLABORATIVE CULTURE AND APPLICATION OF NEW TECHNOLOGIES AND DATA ANALYTICS IN A QUEST TO UNDERSTAND WHAT CAN CAUSE THE IMMUNE SYSTEM TO FALL OUT OF BALANCE AND HOW TO RESTORE IT TO HEALTH. TO THAT END, OUR SCIENTIFIC ACTIVITIES ARE ORGANIZED INTO FOUR CENTERS OF DISCOVERY TO FACILITATE KNOWLEDGE SHARING AND FOR CENTERS AND CORE LABS TO BUILD ON DISCOVERIES FROM INDIVIDUAL LABS: - TRANSLATIONAL IMMUNOLOGY, DIRECTED BY KAREN CEROSALETTI, PHD - INTERVENTIONAL IMMUNOLOGY, DIRECTED BY CARLA GREENBAUM, MD - FUNDAMENTAL IMMUNOLOGY, DIRECTED BY DANIEL CAMPBELL, PHD - SYSTEMS IMMUNOLOGY, DIRECTED BY ADAM LACY-HULBERT, PHD THE CENTER FOR TRANSLATIONAL IMMUNOLOGY (CTI) INVOLVES STUDYING BLOOD AND TISSUE SAMPLES FROM PEOPLE WITH IMMUNE SYSTEM DISEASES INCLUDING AUTOIMMUNE DISEASES, ALLERGIES, INFECTIOUS DISEASES AND CANCER. CTI USES ADVANCED SYSTEMS IMMUNOLOGY TOOLS TO EXAMINE GENES, CELLS AND MOLECULES INVOLVED IN THESE DISEASES. ITS STUDIES AIM TO DISCOVER HOW DISEASES START AND PROGRESS; IDENTIFY BIOLOGICAL CHARACTERISTICS TIED TO CERTAIN DISEASES OR RESPONSE TO THERAPY; AND TO FIND NEW DRUG TARGETS. THE BRI BIOREPOSITORY IS A COLLECTION OF BLOOD, SERUM AND TISSUE SAMPLES AND MEDICAL HISTORIES FROM VOLUNTEERS WITH AND WITHOUT DISEASE. BRI SCIENTISTS AND PHYSICIAN COLLABORATORS WORK TOGETHER TO STUDY TISSUE, BLOOD AND SERUM SAMPLES ALONG WITH THE MEDICAL AND DEMOGRAPHIC DATA. BRI'S BIOREPOSITORIES DATE BACK TO 2000 AND INCLUDE MULTIPLE DISEASE CATEGORIES AND A BIOREPOSITORY OF HEALTHY PEOPLE FOR PURPOSES OF COMPARISON. THE CENTER FOR INTERVENTIONAL IMMUNOLOGY (CII) USES SMALL AND LARGE-SCALE CLINICAL STUDIES TO TRANSLATE LAB DISCOVERIES TO PATIENT THERAPIES. CII STUDIES ENCOMPASS ALL PHASES OF CLINICAL RESEARCH, FROM BRI'S BIOREPOSITORIES, WHICH ENROLL INDIVIDUALS WITH AND WITHOUT IMMUNE SYSTEM DISEASES, TO MULTI-CENTER CLINICAL TRIALS OF DISEASE-MODIFYING THERAPIES. INVESTIGATOR-INITIATED STUDIES OF SHORT-COURSE IMMUNOTHERAPY OR VACCINES SHOW HOW PERTURBING THE IMMUNE SYSTEM CAN REVEAL THE DIFFERENTIAL FUNCTIONS OF THE IMMUNE SYSTEM IMPACTED BY DISEASE. THE IMMUNE TOLERANCE NETWORK, A GLOBAL CONSORTIUM FOCUSED ON CONDUCTING CLINICAL TRIALS TO PROMOTE TOLERANCE IN AUTOIMMUNITY, ORGAN TRANSPLANT AND ALLERGY/ASTHMA IS PART OF THIS CENTER. THE CENTER FOR FUNDAMENTAL IMMUNOLOGY (CFI) INVESTIGATES THE IMMUNE SYSTEM TO UNDERSTAND HOW IT WORKS IN HEALTH AND DISEASE. INVESTIGATORS IN THE CFI LOOK AT THE CELLULAR AND MOLECULAR PATHWAYS THAT CONTROL THE IMMUNE SYSTEM, FOCUSING ON GENES, CELLS AND MOLECULES TO BUILD COMPLEX MODELS OF AUTOIMMUNE AND INFLAMMATORY DISEASES TO STUDY THEM IN PRECISE DETAIL. THE CENTER FOR SYSTEMS IMMUNOLOGY (CSI) USES THE LATEST COMPUTATIONAL TOOLS TO COLLECT, PROCESS AND EXAMINE DATA FROM STUDIES ACROSS BRI AND AROUND THE WORLD. CSI SELECTS AND IMPLEMENTS NEW TECHNOLOGIES AND DEVELOPS APPROACHES TO ORGANIZE AND ANALYZE LARGE DATA SETS. ITS GOAL IS TO MAKE NEW INSIGHTS ABOUT THE IMMUNE SYSTEM AND THE DISEASES THAT AFFECT IT. EXTERNAL AND ACADEMIC AFFAIRS AT BRI WE BUILD THE NEXT GENERATION OF LEADERS IN IMMUNOLOGY BY WORKING ACROSS OUR CENTERS WITH INTERNS, GRADUATE STUDENTS AND POSTDOCS. WE ALSO TEAM UP WITH OTHER RESEARCH INSTITUTES AND INDUSTRY PARTNERS TO TACKLE NEW RESEARCH QUESTIONS AND ACCELERATE DISCOVERIES. JESSICA HAMERMAN, PHD, IS OUR DIRECTOR FOR ACADEMIC AFFAIRS AND STEVEN ZIEGLER, PHD IS OUR DIRECTOR OF EXTERNAL COLLABORATION. IN 2024, BRI'S SUSANA OROZCO, PHD, WAS AWARDED A COMPUTATIONAL SKILLS GRANT FROM THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS (AAI). WITH THIS GRANT, SHE'LL LEARN SOME OF THE LATEST COMPUTATIONAL TECHNIQUES FROM BRI'S HANNAH DEBERG, PHD, AND APPLY THEM TO HER RESEARCH STUDYING INFLAMMATORY HEMOPHAGOCYTES A TYPE OF CELL THAT PLAYS A ROLE IN DEADLY COMPLICATIONS OF RHEUMATIC DISEASES AND MALARIA. BRI PRESIDENT JANE BUCKNER, MD, RECEIVED AAI'S 2024 STEINMAN AWARD FOR HUMAN IMMUNOLOGY RESEARCH, WHICH RECOGNIZES AN INDIVIDUAL WHO HAS MADE SIGNIFICANT CONTRIBUTIONS TO THE UNDERSTANDING OF IMMUNE PROCESSES UNDERLYING HUMAN DISEASE PATHOGENESIS, PREVENTION OR THERAPY. AAI NAMED BRI'S STEVEN ZIEGLER, PHD, A DISTINGUISHED FELLOW, WHICH ACKNOWLEDGES ACTIVE, LONG-TERM AAI MEMBERS WHO HAVE DEMONSTRATED SIGNIFICANT RESEARCH ACCOMPLISHMENT, EXCEPTIONAL LEADERSHIP TO THE IMMUNOLOGY COMMUNITY, AND/OR DISTINCTION IN EDUCATION AND TEACHING. OVER THE PAST FISCAL YEAR, BRI HAS ALSO ENGAGED WITH MANY LOCAL ORGANIZATIONS THAT ENCOURAGE STUDENTS TO CONSIDER CAREERS IN SCIENCE AND HEALTHCARE. BRI HOSTED VIRTUAL SEMINARS FOR WASHINGTON STATE OPPORTUNITY SCHOLARSHIP (WSOS) STEM, CAREER AND TECHNICAL SCHOLARS. THESE SEMINARS INTRODUCE STUDENTS TO OUR INSTITUTE, WHAT WE DO AND HOW STAFF AND RESEARCHERS WORK TOGETHER TO ADVANCE SCIENCE THAT WILL PREDICT, PREVENT, REVERSE AND CURE DISEASES OF THE IMMUNE SYSTEM. OVER THE PAST FISCAL YEAR, BRI HAS ALSO ENGAGED WITH MANY LOCAL ORGANIZATIONS THAT ENCOURAGE STUDENTS TO CONSIDER CAREERS IN SCIENCE AND HEALTHCARE. BRI STAFF TALK TO STUDENTS ABOUT OUR INSTITUTE, WHAT WE DO AND HOW STAFF AND RESEARCHERS WORK TOGETHER TO ADVANCE SCIENCE THAT WILL PREDICT, PREVENT, REVERSE AND CURE DISEASES OF THE IMMUNE SYSTEM.
FORM 990, PART VI, SECTION A, LINE 1A	THE GOVERNING BODY DELEGATES TO AN EXECUTIVE COMMITTEE COMPRISED OF FOUR OFFICERS OF THE BOARD AND THE CHAIRS OF EACH STANDING BOARD COMMITTEE, THE AUTHORITY OF THE BOARD OF DIRECTORS IN THE MANAGEMENT OF THE CORPORATION AS MAY BE DEEMED BY THE EXECUTIVE COMMITTEE TO BE APPROPRIATE, TO BE EXERCISED IN TIME PERIODS BETWEEN REGULARLY SCHEDULED MEETINGS OF THE BOARD OF DIRECTORS; PROVIDED THAT THE EXECUTIVE COMMITTEE HAS THE AUTHORITY TO ACT ONLY IN TIME SENSITIVE OR EMERGENCY SITUATIONS. THE DIRECTOR AND THE EXECUTIVE DIRECTOR OF THE CORPORATION SERVE AS EX OFFICIO MEMBERS OF THE EXECUTIVE COMMITTEE WITHOUT VOTING RIGHTS. THE EXECUTIVE COMMITTEE DOES NOT HAVE THE AUTHORITY TO AMEND, ALTER OR REPEAL THE BYLAWS; ELECT, APPOINT OR REMOVE ANY MEMBER OF SUCH EXECUTIVE COMMITTEE OR ANY DIRECTOR OR OFFICER OF THE CORPORATION; AMEND THE ARTICLES OF INCORPORATION; ADOPT A PLAN OF MERGER OR ADOPT A PLAN OF CONSOLIDATION WITH ANOTHER CORPORATION; AUTHORIZE THE SALE, LEASE OR EXCHANGE OF ALL OR SUBSTANTIALLY ALL THE PROPERTY AND ASSETS OF THE CORPORATION NOT IN THE ORDINARY COURSE OF BUSINESS; AUTHORIZE THE VOLUNTARY DISSOLUTION OF THE CORPORATION OR REVOKE PROCEEDINGS THEREFORE; ADOPT A PLAN FOR THE DISTRIBUTION OF THE ASSETS OF THE CORPORATION; OR AMEND, ALTER OR REPEAL ANY RESOLUTION OF THE BOARD WHICH BY ITS TERMS PROVIDES THAT IT SHALL NOT BE AMENDED, ALTERED OR REPEALED BY SUCH EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE ALSO SERVES AS THE PLANNING COMMITTEE FOR THE BOARD OF DIRECTORS AND OVERSEES ANY COMPLIANCE ISSUES RAISED BY THE BOARD OF DIRECTORS.
FORM 990, PART VI, SECTION A, LINE 6	ACCORDING TO THE BYLAWS OF BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON THE ENTITY'S SOLE MEMBER IS VIRGINIA MASON FRANCISCAN HEALTH, A WASHINGTON NONPROFIT CORPORATION.
FORM 990, PART VI, SECTION A, LINE 7A	VIRGINIA MASON FRANCISCAN HEALTH ("VMFH") IS THE SOLE CORPORATE MEMBER OF BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON ("BRI"). ACCORDING TO THE ORGANIZATION'S BYLAWS, DIRECTORS SHALL BE APPOINTED OR REFUSED BY THE CORPORATE MEMBER. THE CORPORATE MEMBER MAY APPOINT ONE OR MORE INDIVIDUALS TO THE BOARD OF DIRECTORS, AND MAY AT ANY TIME REMOVE, WITH OR WITHOUT CAUSE, ANY MEMBER OF THE BOARD OF DIRECTORS.
FORM 990, PART VI, SECTION A, LINE 7B	VIRGINIA MASON FRANCISCAN HEALTH ("VMFH") IS THE SOLE CORPORATE MEMBER OF BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON ("BRI"). EXCEPT AS OTHERWISE PROVIDED IN THE CORPORATION'S ARTICLES OF INCORPORATION, ELSEWHERE IN THESE BYLAWS, OR IN THE LAWS OF THE STATE OF WASHINGTON, THE CORPORATE MEMBER SHALL HAVE THE SPECIFIC RIGHTS SET FORTH IN THE GOVERNANCE MATRIX. THE RIGHTS OF THE CORPORATE MEMBER SHALL BE FURTHER SUBJECT TO THE POWERS RESERVED TO CSH UNDER THE GOVERNANCE MATRIX (SUBJECT TO THE BYLAWS OF THE CORPORATE MEMBER) AND AS OTHERWISE SET FORTH IN THE BYLAWS OF THE CORPORATE MEMBER. IN ADDITION, SUBJECT TO THE BYLAWS OF THE CORPORATE MEMBER, THE RESERVED POWERS OF CSH SET FORTH IN THE GOVERNANCE MATRIX MAY BE UNILATERALLY EXERCISED BY CSH ON BEHALF OF THE CORPORATION, AT CSH'S SOLE DISCRETION, IF THE CORPORATION'S BOARD OF DIRECTORS FAILS TO ACT UPON SUCH MATTERS DESCRIBED IN THESE BYLAWS, OR IF THE CORPORATION'S BOARD OF DIRECTORS ATTEMPTS TO ACT IN A MANNER THAT CONFLICTS WITH OR OVERRIDES THE ACTIONS OR DESIRES OF CSH WITH RESPECT TO SUCH MATTERS. THE GOVERNANCE MATRIX MAY BE AMENDED FROM TIME TO TIME BY CSH, AND SUCH AMENDMENTS SHALL BE DEEMED TO BE A PART OF THESE BYLAWS WITHOUT FURTHER ACTION. THE CORPORATION SHALL BE DEEMED A "SUBSIDIARY" OF CSH FOR PURPOSES OF THE GOVERNANCE MATRIX. IN ADDITION TO THE RIGHTS RESERVED TO CSH UNDER THE GOVERNANCE MATRIX, CSH SHALL HAVE THE POWER TO TRANSFER ASSETS OF THE CORPORATION OR TO REQUIRE THE CORPORATION TO TRANSFER ASSETS TO CSH, TO THE EXTENT NECESSARY TO ACCOMPLISH CSH'S GOALS AND OBJECTIVES, AND TO PROVIDE FOR THE PAYMENT OF ALL INDEBTEDNESS OF CSH OR AN ENTITY CONTROLLED BY, CONTROLLING, OR UNDER COMMON CONTROL WITH CSH (FOR PURPOSES OF THIS SECTION, A "CSH AFFILIATE"), ISSUED OR INCURRED BY OR ON BEHALF OF CSH OR A CSH AFFILIATE IN FURTHERANCE OF CSH'S GOALS AND OBJECTIVES. THE CORPORATION SHALL NOT BE REQUIRED TO VIOLATE ITS CHARITABLE PURPOSES, THESE BYLAWS OR ITS ARTICLES OF INCORPORATION, THE TERMS OF ANY RESTRICTED GIFTS, OR THE COVENANTS OF ITS DEBT INSTRUMENTS OR OTHER CONTRACTS AS A RESULT OF ANY ASSET TRANSFERS MADE OR DIRECTED BY CSH. EXCEPT FOR TRANSFERS PREVIOUSLY APPROVED BY CSH, EITHER INDIVIDUALLY OR AS PART OF THE CSH HEALTHCARE SYSTEM BUDGET PROCESS, AND EXCEPT FOR TRANSFERS TO AN AFFILIATE OR SUBSIDIARY OF THE CORPORATION, THE CORPORATION SHALL NOT TRANSFER ASSETS TO ENTITIES OTHER THAN CSH OR CSH AFFILIATES WITHOUT THE APPROVAL OF CSH.
FORM 990, PART VI, SECTION B, LINE 11B	NO REVIEW WAS OR WILL BE CONDUCTED.
FORM 990, PART VI, SECTION B, LINE 12C	THE ORGANIZATION HAS A CONFLICTS OF INTEREST ("COI") POLICY (THE "POLICY") IN PLACE TO PROTECT THE INTERESTS OF COMMONSPIRIT HEALTH ("COMMONSPIRIT") IN CIRCUMSTANCES THAT MAY RESULT IN A CONFLICT BETWEEN PERSONAL INTERESTS OF A PERSON AND THE INTERESTS OF THE ORGANIZATION AND THOSE IT SERVES. COMMONSPIRIT'S COI POLICY APPLIES TO COMMONSPIRIT, ITS DIRECT AFFILIATES AND SUBSIDIARIES AND ANY RELATED ENTITY THE GOVERNING DOCUMENTS OF WHICH REQUIRE THE ENTITY TO COMPLY WITH COMMONSPIRIT POLICY (COLLECTIVELY THE "SYSTEM ENTITIES"). THE FOLLOWING PERSONS ARE REQUIRED TO DISCLOSE ACTUAL OR POTENTIAL CONFLICTS OF INTEREST AT LEAST ANNUALLY (VIA A FORMAL SYSTEM-ADMINISTERED SURVEY) IF THE PERSON'S AFFILIATION WITH COMMONSPIRIT CONTINUES: - MEMBERS OF CORPORATE AND COMMUNITY BOARDS OF SYSTEM ENTITIES - MEMBERS OF COMMITTEES OF CORPORATE AND COMMUNITY BOARDS OF SYSTEM ENTITIES - MEMBERS OF THE EXECUTIVE LEADERSHIP TEAM ("ELT") OF COMMONSPIRIT - CORPORATE OFFICERS OF SYSTEM ENTITIES - EMPLOYED PHYSICIANS AND ADVANCED PRACTICE PROVIDERS - KEY EMPLOYEES AND HIGHEST COMPENSATED EMPLOYEES AS SPECIFIED BY THE INTERNAL REVENUE SERVICE FOR FORM 990 PURPOSES WHO ARE NOT OTHERWISE INCLUDED IN THE CATEGORIES ABOVE - EMPLOYEES OF SYSTEM ENTITIES AT THE VICE PRESIDENT LEVEL AND ABOVE - ALL INDIVIDUALS ENGAGED IN RESEARCH AT INSTITUTIONS OWNED OR OPERATED BY A SYSTEM ENTITY - SELECT EMPLOYEES AS DETERMINED FROM TIME TO TIME BY LEADERSHIP DISCLOSURE, REVIEW, AND MANAGEMENT OF PERCEIVED, POTENTIAL, OR ACTUAL CONFLICTS OF INTEREST ARE ACCOMPLISHED THROUGH A DEFINED COI DISCLOSURE REVIEW PROCESS. EACH PERSON IS REQUIRED TO PROMPTLY AND FULLY DISCLOSE ANY SITUATION OR CIRCUMSTANCE THAT MAY CREATE A CONFLICT OF INTEREST AS SOON AS SHE/HE BECOMES AWARE OF IT. IN ADDITION, AT THE INCEPTION OF AN INDIVIDUAL'S RELATIONSHIP WITH COMMONSPIRIT (E.G. HIRING, BOARD APPOINTMENT), AND FOR CERTAIN POSITIONS, ANNUALLY THEREAFTER, WRITTEN CONFLICT OF INTEREST DISCLOSURE FORMS MUST BE COMPLETED. A FAILURE TO DISCLOSE MAY RESULT IN DISCIPLINARY OR CORRECTIVE ACTIONS. REPORTED POTENTIAL OR ACTUAL CONFLICTS OF INTEREST ARE INITIALLY REVIEWED BY LEGAL, CORPORATE RESPONSIBILITY OR RESEARCH INTEGRITY STAFF. IF NECESSARY, A CONFLICT OF INTEREST MANAGEMENT PLAN IS DEVELOPED, WHICH PLAN SHALL BE SUBJECT TO ACCEPTANCE BY THE APPROPRIATE DIRECT MANAGER, SUPERVISOR, MEDICAL STAFF OFFICE, BOARD OR BOARD COMMITTEE (FOR BOARD, BOARD COMMITTEE, ELT OR CORPORATE OFFICER CONFLICTS), OR OTHER APPROPRIATE INDIVIDUAL OR BODY. ONCE ACCEPTED, THE CONFLICT OF INTEREST MANAGEMENT PLAN IS COMMUNICATED TO THE PERSON WITH THE ACTUAL OR POTENTIAL CONFLICT AND THE INDIVIDUAL MUST CONDUCT THEMSELVES IN CONFORMITY WITH THE PLAN. IN THE EVENT THAT A TRANSACTIONAL CONFLICT INTEREST ARISES IN CONNECTION WITH A SYSTEM ENTITY BOARD MEETING, THE CONFLICTED INDIVIDUAL MUST DISCLOSE THAT CONFLICT PRIOR TO OR AT THE BEGINNING OF THE MEETING IN WHICH THE MATTER IS TO BE CONSIDERED. THE CONFLICTED INDIVIDUAL IS EXCLUDED FROM VOTING ON THE TRANSACTION AND IS PROHIBITED FROM USING PERSONAL INFLUENCE WITH RESPECT TO THE MATTER, BUT IS NOT PROHIBITED FROM PROVIDING INPUT IF REQUESTED TO DO SO.
FORM 990, PART VI, SECTION B, LINE 15	THE VMMC COMPENSATION AND BENEFITS BOARD COMMITTEE, A COMMITTEE COMPOSED SOLELY OF INDEPENDENT DIRECTORS NONE OF WHOM HAVE A CONFLICT OF INTEREST, IS ACCOUNTABLE FOR SETTING REASONABLE TOTAL COMPENSATION PACKAGES THE PRESIDENT AND CHIEF EXECUTIVE CONSISTENT WITH BRI'S COMPENSATION PHILOSOPHY AND PRINCIPLES. THE COMMITTEE APPROVES ANNUAL GOALS AND PERFORMANCE CRITERIA WHICH ARE USED IN DETERMINING MERIT INCREASES AND VARIABLE COMPENSATION OPPORTUNITIES. THE COMMITTEE ASSESSES PERFORMANCE AGAINST THESE GOALS. THE COMMITTEE SELECTS AND ENGAGES A QUALIFIED INDEPENDENT COMPENSATION CONSULTANT TO REVIEW AND ANALYZE THE TOTAL COMPENSATION AND BENEFITS PACKAGES OF THE EXECUTIVES. THE COMMITTEE AS PART OF ITS ANALYSIS OBTAINS FROM THE COMPENSATION CONSULTANT APPROPRIATE COMPARABILITY DATA INCLUDING TOTAL COMPENSATION PAID BY SIMILARLY SITUATED ORGANIZATIONS FOR POSITIONS THAT ARE FUNCTIONALLY COMPARABLE TO EACH OF THE EXECUTIVES. THE COMMITTEE WILL CONSIDER THE SIGNIFICANT TERMS OF THE AGREEMENT WITH EACH EXECUTIVE INCLUDING THE TOTAL COMPENSATION TO BE PAID AND THE EMPLOYEE'S DUTIES AND RESPONSIBILITIES. CONSISTENT WITH THE COMPENSATION PHILOSOPHY AND PRINCIPLES, THE COMMITTEE APPROVES TOTAL COMPENSATION PACKAGES FOR EACH OF THE EXECUTIVES BASED ON INFORMATION PRESENTED TO THE COMMITTEE, REASONABLENESS, AND THE BEST INTEREST OF BRI. THE COMMITTEE'S DECISIONS REGARDING COMPENSATION FOR EACH EXECUTIVE ARE DOCUMENTED IN WRITTEN RESOLUTIONS AND MINUTES OF THE COMMITTEE. THE COMMITTEE PROMPTLY REPORTS ITS ACTIONS TO THE VMMC BOARD WHICH REPORTS ARE REFLECTED IN THE BOARD'S MINUTES.
FORM 990, PART VI, SECTION C, LINE 19	THE ORGANIZATION'S ARTICLES, BYLAWS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE MADE AVAILABLE UPON REQUEST.

Schedule R IRS990ScheduleR

Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp

Disregarded Entity Name DisregardedEntityName

Field	Value	IRS element (for citing)
Business Name Line1	VIRGINIA MASON FRANCISCAN HEALTH	BusinessNameLine1Txt

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	1149 MARKET ST	AddressLine1Txt
City	TACOMA	CityNm
State Abbreviation	WA	StateAbbreviationCd
ZIP	98402	ZIPCd

Field	Value	IRS element (for citing)
EIN	861332353	EIN
Primary Activities	HEALTH CARE	PrimaryActivitiesTxt
Legal Domicile State	WA	LegalDomicileStateCd
Exempt Code Section	501(C)(3)	ExemptCodeSectionTxt
Public Charity Status	LINE 12B, II	PublicCharityStatusTxt
Direct Controlling NA	N/A	DirectControllingNACd
Controlled Organization	0	ControlledOrganizationInd

Field	Value	IRS element (for citing)
Receipt Of Int Annts Rnts Rylts	0	ReceiptOfIntAnntsRntsRyltsInd
Gift Grnt Or Cap Contri To Oth Org	0	GiftGrntOrCapContriToOthOrgInd
Gift Grnt Cap Contri From Oth Org	0	GiftGrntCapContriFromOthOrgInd
Loans Or Guarantees To Other Org	0	LoansOrGuaranteesToOtherOrgInd
Loans Or Guarantees From Oth Org	0	LoansOrGuaranteesFromOthOrgInd
Div Related Organization	0	DivRelatedOrganizationInd
Asset Sale To Other Org	0	AssetSaleToOtherOrgInd
Asset Purchase From Other Org	0	AssetPurchaseFromOtherOrgInd
Asset Exchange	0	AssetExchangeInd
Rental Of Facilities To Oth Org	0	RentalOfFacilitiesToOthOrgInd
Rental Of Fclts From Oth Org	0	RentalOfFcltsFromOthOrgInd
Perform Of Services For Oth Org	0	PerformOfServicesForOthOrgInd
Perform Of Services By Other Org	0	PerformOfServicesByOtherOrgInd
Sharing Of Facilities	0	SharingOfFacilitiesInd
Paid Employees Sharing	0	PaidEmployeesSharingInd
Reimbursement Paid To Other Org	0	ReimbursementPaidToOtherOrgInd
Reimbursement Paid By Other Org	0	ReimbursementPaidByOtherOrgInd
Transfer To Other Org	0	TransferToOtherOrgInd
Transfer From Other Org	0	TransferFromOtherOrgInd

Affiliated Group Schedule AffiliatedGroupSchedule

Affiliated Schedule AffiliatedScheduleGrp (3 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	EINEIN	Total Grassroots LobbyTotalGrassrootsLobbyAmt	Total Direct LobbyTotalDirectLobbyAmt	Total Lobby ExpenditureTotalLobbyExpenditureAmt	Other Exempt Purpose ExpendOtherExemptPurposeExpendAmt	Total Exempt Purpose ExpendTotalExemptPurposeExpendAmt	Lobby NontxLobbyNontxAmt	Grassroots NontxGrassrootsNontxAmt	Total Lobby Grssroot Mns NontxTotalLobbyGrssrootMnsNontxAmt	Tot Lbby Expend Mns Lobby NontxTotLbbyExpendMnsLobbyNontxAmt	Share Excess Lobby ExpendShareExcessLobbyExpendAmt	Electing OrganizationElectingOrganizationInd
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON
1201 NINTH AVENUE	SEATTLE	WA	98101	910653422	$0	$0	$0	$73,646,780	$73,646,780	$1,000,000	$250,000	$0	$0	$0
VIRGINIA MASON MEDICAL CENTER
1100 NINTH AVENUE	SEATTLE	WA	98101	910565539	$169,379	$0	$169,379	$1,201,243,010	$1,201,412,389	$1,000,000	$250,000	$0	$0	$0	Yes (X)
VIRGINIA MASON INSTITUTE
1100 NINTH AVENUE	SEATTLE	WA	98101	263763656	$0	$0	$0	$2,778,994	$2,778,994	$288,950	$72,238	$0	$0	$0